<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1306210785
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Trazimera
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Trastuzumab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        440
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3019.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Trazimera contains the active substance trastuzumab, which is a monoclonal antibody. Monoclonal antibodies attach to specific proteins or antigens. Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When Trazimera binds to HER2 it stops the growth of such cells and causes them to die.</p><p><strong>&nbsp;</strong></p><p>Your doctor may prescribe Trazimera for the treatment of breast and gastric cancer when:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have early breast cancer, with high levels of a protein called HER2.<br />&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have metastatic breast cancer (breast cancer that has spread beyond the original tumour) with high levels of HER2. Trazimera may be prescribed in combination with the chemotherapy medicine paclitaxel or docetaxel as first treatment for metastatic breast cancer or it may be prescribed alone if other treatments have proved unsuccessful. It is also used in combination with medicines called aromatase inhibitors with patients with high levels of HER2 and hormone receptor-positive metastatic breast cancer (cancer that is sensitive to the presence of female sex hormones).</p><p>&nbsp;</p><p>You have metastatic gastric cancer with high levels of HER2, when it is in combination with the other cancer medicines capecitabine or 5-flououracil and cisplatin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Trazimera if:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to trastuzumab, to hamster (CHO) cell protein, or to any of the other ingredients of this medicine or solvent (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In metastatic breast cancer and in adjuvant treatment, Trazimera and anthracyclines should not be administered concomitantly. In neoadjuvant treatment, the concomitant administration of Trazimera and anthracyclines must be applied with caution, and only in chemotherapy-naive patients.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe breathing problems at rest due to your cancer or if you need oxygen treatment.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Your doctor will closely supervise your therapy.</p><p>&nbsp;</p><p><strong>Heart checks</strong></p><p>Treatment with Trazimera alone or with a taxane may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine used to treat cancer). The effects may be moderate to severe and could cause death. Therefore, your heart function will be checked before, during (every three months) and after (up to two to five years) treatment with Trazimera. If you develop any signs of heart failure (inadequate pumping of blood by the heart), your heart function may be checked more frequently (every six to eight weeks), you may receive treatment for heart failure or you may have to stop Trazimera treatment.</p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before you are given Trazimera if:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had heart failure, coronary artery disease, heart valve disease (heart murmurs), high blood pressure, taken any high blood pressure medicine or are currently taking any high blood pressure medicine.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had or are currently using a medicine called doxorubicin or epirubicin (medicines used to treat cancer). These medicines (or any other anthracyclines) can damage heart muscle and increase the risk of heart problems with Trazimera.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suffer from breathlessness, especially if you are currently using a taxane. Trazimera can cause breathing difficulties, especially when it is first given. This could be more serious if you are already breathless. Very rarely, patients with severe breathing difficulties before treatment have died when they were given Trazimera.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had any other treatment for cancer.</p><p>&nbsp;</p><p>If you receive Trazimera with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin you should also read the patient information leaflets for these products.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The use and safety of trastuzumabin children and adolescents &lt;18 years has not yet been investigated.</p><p>&nbsp;</p><p><strong>Other medicines and Trazimera</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or may take any other medicines.</p><p>&nbsp;</p><p>It may take up to 7 months for Trazimera to be removed from the body. Therefore you should tell your doctor, pharmacist or nurse that you have had Trazimera if you start any new medicine in the 7&nbsp;months after stopping treatment.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should use effective contraception during treatment with Trazimera and for at least 7&nbsp;months after treatment has ended.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will advise you of the risks and benefits of taking Trazimera during pregnancy. In rare cases, a reduction in the amount of (amniotic) fluid that surrounds the developing baby within the womb has been observed in pregnant women receiving Trazimera. This condition may be harmful to your baby in the womb and has been associated with the lungs not developing fully resulting in foetal death.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Do not breast-feed your baby during Trazimera therapy and for 7 months after the last dose of Trazimera as Trazimera may pass to your baby through your breast milk.</p><p><strong>&nbsp;</strong></p><p><strong>Fertility</strong></p><p>There is no fertility data available.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Trazimera may affect your ability to drive a car or operate machines. If during treatment you experience symptoms, such as dizziness, sleepiness, chills or fever, you should not drive or use machines until these symptoms disappear.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before starting the treatment your doctor will determine the amount of HER2 in your tumour. Only patients with a large amount of HER2 will be treated with Trazimera. Trazimera should only be given by a doctor or nurse. Your doctor will prescribe a dose and treatment regimen that is right for <strong><em>you</em></strong>. The dose of Trazimera depends on your body weight.</p><p>&nbsp;</p><p>Trazimera intravenous formulation is not for subcutaneous use and should be given as an intravenous infusion only.</p><p>&nbsp;</p><p>Trazimera intravenous formulation is given as an intravenous infusion (&ldquo;drip&rdquo;) directly into your veins. The first dose of your treatment is given over 90 minutes and you will be observed by a health professional while it is being given in case you have any side effects. If the first dose is well tolerated the next doses may be given over 30 minutes (see section 2 under &ldquo;Warnings and precautions&rdquo;). The number of infusions you receive will depend on how you respond to the treatment. Your doctor will discuss this with you.</p><p>&nbsp;</p><p>In order to prevent medication errors it is important to check the vial labels to ensure that the medicine being prepared and given is Trazimera (trastuzumab) and not trastuzumab emtansine.</p><p>&nbsp;</p><p>For early breast cancer, metastatic breast cancer and metastatic gastric cancer, Trazimera is given every 3 weeks. Trazimera may also be given once a week for metastatic breast cancer.</p><p>&nbsp;</p><p><strong>If you missed to use </strong><strong>Trazimera</strong><strong> </strong></p><p>If you missed a Trazimera dose and:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is within a period of one week at the most, the usual maintenance dose should be administered as soon as possible. Then Trazimera maintenance doses should be administered 7 or 21 days later, in accordance with either the weekly or three-week treatment regimen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is more than one week, an initial dose of Trazimera over 90 minutes should be administered again as soon as possible. Then Trazimera maintenance doses should be administered 7 or 21 days later, in accordance with either the weekly or three-week treatment regimen.</p><p>&nbsp;</p><p><strong>If you stop using Trazimera</strong></p><p>Do not stop using this medicine without talking to your doctor first. All doses should be taken at the right time every week or every three weeks (depending on your dosing schedule). This helps your medicine work as well as it can.</p><p>&nbsp;</p><p>It may take up to 7 months for Trazimera to be removed from your body. Therefore, your doctor may decide to continue to check your heart functions, even after you finish treatment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Trazimera can cause side effects, although not everybody gets them. Some of these side effects may be serious and may lead to hospitalisation.</p><p>&nbsp;</p><p>During a Trazimera infusion, chills, fever and other flu like symptoms may occur. These are very common (may affect more than 1 in 10 people). Other infusion-related symptoms are: feeling sick (nausea), vomiting, pain, increased muscle tension and shaking, headache, dizziness, breathing difficulties, wheezing, high or low blood pressure, heart rhythm disturbances (palpitations, heart fluttering or irregular heart beat), swelling of the face and lips, rash and feeling tired. Some of these symptoms can be serious and some patients have died (see section 2 under &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>These effects mainly occur with the first intravenous infusion (&ldquo;drip&rdquo; into your vein) and during the first few hours after the start of the infusion. They are usually temporary. You will be observed by a healthcare professional during the infusion and for at least six hours after the start of the first infusion and for two hours after the start of other infusions. If you develop a reaction, they will slow down or stop the infusion and may give you treatment to counteract the side effects. The infusion may be continued after the symptoms improve.</p><p>&nbsp;</p><p>Occasionally, symptoms start later than six hours after the infusion begins. If this happens to you, contact your doctor immediately. Sometimes, symptoms may improve and then get worse later.</p><p>&nbsp;</p><p>Serious side effects:</p><p>Other side effects can occur at any time during treatment with Trazimera, not just related to an infusion.</p><p><strong>Tell a doctor or nurse straight away, if you notice any of the following side effects:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart problems can sometimes occur during treatment and occasionally after treatment has stopped and can be serious. They include weakening of the heart muscle possibly leading to heart failure, inflammation of the lining around the heart and heart rhythm disturbances. This can lead to symptoms such as breathlessness (including breathlessness at night), cough, fluid retention (swelling) in the legs or arms, and palpitations (heart fluttering or irregular heart beat) (see section 2 under &ldquo;Heart checks&rdquo;).</p><p>&nbsp;</p><p>Your doctor will monitor your heart regularly during and after treatment but you should tell your doctor immediately if you notice any of the above symptoms.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumour lysis syndrome (a group of metabolic complications occurring after cancer treatment characterised by high blood levels of potassium and phosphate, and low blood levels of calcium). Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (fluttering of the heart or a faster or slower heartbeat), seizures, vomiting or diarrhoea, and tingling in the mouth, hands or feet.</p><p>&nbsp;</p><p>If you experience any of the above symptoms when your treatment with Trazimera has finished, you should see your doctor and tell them that you have previously been treated with Trazimera.</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10 people:</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn (dyspepsia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low counts of red blood cells and white blood cells (which help fight infection) sometimes with fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; conjunctivitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; watery eyes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny nose</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nail disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to sleep (insomnia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low platelet count</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling of the fingers and toes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, swelling or sores in your mouth and/or throat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, swelling, redness or tingling of hands and/or feet</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people: </strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry eyes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat infections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bladder and skin infections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak and unwell&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the breast&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased muscle tone or tension &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of lungs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (hypertonia)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the arms and/or legs&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neck pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness (somnolence)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemorrhoids&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchiness&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leg cramps</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;dry mouth and skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people:</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deafness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bumpy rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation or scarring of the lungs</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people:</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylactic reactions</p><p>&nbsp;</p><p>&nbsp;<strong>Not known: frequency cannot be estimated from the available data:</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal or impaired blood clotting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high potassium levels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or bleeding at the back of the eyes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shock</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory distress</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute accumulation of fluid in the lungs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute narrowing of the airways</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormally low oxygen levels in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing when lying flat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver damage</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips and throat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormally low levels of fluid around baby in womb</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure of the lungs of the baby to develop in the womb</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal development of the kidneys of the baby in the womb</p><p>&nbsp;</p><p>Some of the side-effects you experience may be due to your underlying cancer. If you receive Trazimera in combination with chemotherapy, some of them may also be due to the chemotherapy.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effect:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC states</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>Please contact the relevant competent authority.</li></ul></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p><strong>Expiry</strong></p><p>Do not use this medicine after the expiry date which is stated on the vial label and carton after &#39;EXP&#39;.&nbsp; Where only a month and year is stated, the expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Storage</strong></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Unopened vials of Trazimera may be stored up to 30&deg;C for a single period of up to 3 months. Discard at the end of this 3-month period or by the expiry date on the vial, whichever occurs first. Record the &ldquo;discard by&rdquo; date in the date field provided on the carton.</p><p>&nbsp;</p><p>Infusion solutions should be used immediately after dilution. Do not use Trazimera if you notice any particulate matter or discoloration prior to administration.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is trastuzumab. One vial contains either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150&nbsp;mg trastuzumab that has to be dissolved in 7.2 mL of sterile water for injections, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 440 mg trastuzumab that has to be dissolved in 20 mL of sterile water for injections.</p><p>The resulting solution contains approximately 21&nbsp;mg/mL trastuzumab.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient(s) are L‑histidine hydrochloride monohydrate, L‑histidine, sucrose, polysorbate 20.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Trazimera is a powder for concentrate for solution for infusion, which is supplied in a glass vial with a rubber stopper containing either 150 mg or 440 mg of trastuzumab. The powder is a white cake. Each carton contains 1 vial of powder. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorization holder:</strong></p><p>Pfizer AG, Z&uuml;rich, Switzerland</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Pfizer Manufacturing Belgium NV, Rijksweg, Puurs, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ترازيميرا على المادة الفعالة تراستوزوماب، وهي جسم مضاد وحيد النسيلة. ترتبط الأجسام المضادة وحيدة النسيلة ببروتينات أو مستضدات معينة. تراستوزوماب مصمم ليرتبط بشكل انتقائي بمستضد يسمى مستقبل عامل النمو البشروي البشري ٢ (HER2). يوجد HER2 بكميات كبيرة على سطح بعض الخلايا السرطانية حيث تحفز نموها. عندما يرتبط ترازيميرا بـHER2، فإنه يوقف نمو تلك الخلايا ويقضي عليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف لك طبيبك ترازيميرا لعلاج سرطان الثدي والمعدة في حالة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابتك بحالة مبكرة من سرطان الثدي، مع مستويات مرتفعة من البروتين المسمى بـHER2.<br />&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابتك بسرطان الثدي النقيلي (سرطان الثدي الذي انتشر في أجزاء أخرى بخلاف منطقة الورم الأصلي) مع مستويات مرتفعة من HER2. قد يتم وصف ترازيميرا بالتزامن مع أدوية العلاج الكيميائي باكليتاكسيل أو دوسيتاكسيل كعلاج أولي لسرطان الثدي النقيلي أو قد يتم وصفه بمفرده في حالة ثبت أن العلاجات الأخرى غير ناجحة. وهو يستخدم أيضًا بالتزامن مع أدوية تسمى مثبطات الأروماتاز مع المرضى الذين لديهم مستويات مرتفعة من HER2 وسرطان الثدي النقيلي الإيجابي لمستقبل الهرمون (سرطان ذو حساسية تجاه الهرمونات الجنسية الأنثوية).<br />&nbsp;</p><p dir="RTL">إصابتك بسرطان المعدة النقيلي مع مستويات مرتفعة من HER2، عند تناوله بالتزامن مع أدوية السرطان الأخرى مثل كابيسيتابين أو 5-فلورويوراسيل وسيسبلاتين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال ترازيميرا</strong> <strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالحساسية تجاه تراستوزوماب أو بروتين خلايا مبيض الهامستر الصيني (CHO) أو تجاه أي مكون آخر من مكونات هذا الدواء أو المذيب (المدرجة في القسم ٦).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات سرطان الثدي النقيلي وفي العلاج المساعد، ينبغي عدم إعطاء ترازيميرا بالتزامن مع مركبات أنثراسيكلين. في حالة العلاج التمهيدي، يجب توخي الحذر عند اللجوء للاستخدام المتزامن لترازيميرا ومركبات أنثراسيكلين وفقط مع المرضى الذين لم يخضعوا للعلاج الكيميائي من قبل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بمشكلات شديدة في التنفس أثناء الراحة نتيجة لإصابتك بالسرطان أو في حالة كنت بحاجة إلى العلاج بالأكسجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ترازيميرا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيشرف طبيبك على علاجك عن كثب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فحوصات القلب</strong></p><p dir="RTL">قد يؤثر العلاج باستخدام ترازيميرا بمفرده أو مع إحدى مركبات التاكسان على القلب، خاصةً إذا سبق أن استخدمت إحدى مركبات الأنثراسيكلين (التاكسانات ومركبات الأنثراسيكلين هما نوعان آخران من الأدوية المستخدمة لعلاج السرطان). قد تكون الآثار متوسطة إلى شديدة وقد تسبب الوفاة. لذلك سيتم فحص وظائف قلبك قبل وأثناء (كل ٣ أشهر) وبعد (ما يصل إلى فترة تتراوح بين عامين و٥ أعوام) العلاج بترازيميرا. إذا أصبت بأي علامة من علامات فشل القلب (ضخ كمية دم غير كافية عن طريق القلب)، فقد يتم فحص وظائف قلبك بمعدل أكثر تكرارًا (كل ٦ إلى ٨ أسابيع)، وقد تتلقى علاجًا لفشل القلب أو قد يتوجب عليك إيقاف العلاج بترازيميرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل أن يتم إعطاؤك ترازيميرا إذا:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد أصبت بفشل القلب، أو مرض الشريان التاجي، أو مرض صمام القلب (النفخات القلبية)، أو ضغط الدم المرتفع، أو سبق أن تناولت أيًا من أدوية ضغط الدم المرتفع أو كنت تتناول حاليًا أيًا من أدوية ضغط الدم المرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد استخدمت أو تستخدم حاليًا دواء يسمى دوكسوروبيسين أو ابيروبسين (أدوية تستخدم لعلاج السرطان). قد تسبب هذه الأدوية (أو أيًا من مركبات الأنثراسيكلين الأخرى) ضررًا لعضلة القلب أو تزيد من خطر الإصابة بمشكلات بالقلب مع ترازيميرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من عدم القدرة على التنفس، خاصةً إذا كنت تستخدم حاليًا إحدى مركبات التاكسان. قد يسبب ترازيميرا صعوبات في التنفس، خاصةً عندما يتم إعطاؤه لأول مرة. قد يكون هذا أكثر خطرًا إذا كنت بالفعل تعاني من صعوبة في التنفس. بشكل نادر جدًا، توفي المرضى الذين كانوا يعانون من صعوبات شديدة في التنفس قبل العلاج عندما تم إعطاؤهم ترازيميرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد تلقيت سابقًا أيًا من علاجات السرطان الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اذا كنت تتلقى ترازيميرا مع أي دواء آخر لعلاج السرطان، مثل باكليتاكسيل، أو دوسيتاكسيل، أو أحد مثبطات الأروماتاز، أو كابيسيتابين، أو 5-فلورويوراسيل، أو سيسبلاتين، ينبغي لك أيضًا قراءة نشرات المعلومات الخاصة بالمريض لتلك المنتجات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم يتم البحث بعد في سلامة واستخدام تراستوزوماب في الأطفال والمراهقين أقل من ١٨ عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أو تناولت حديثًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تستغرق إزالة ترازيميرا من الجسم مدة تصل إلى ٧ أشهر. لذلك ينبغي لك إخبار طبيبك أو الصيدلي أو الممرضة إذا بدأت بتلقي أي دواء جديد أنك قد تناولت ترازيميرا في مدة الـ٧ أشهر بعد توقفك عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي أو الممرضة قبل تناول هذا الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي لكِ استخدام وسيلة فعالة لمنع الحمل أثناء العلاج بترازيميرا ولمدة ٧ أشهر على الأقل بعد انتهاء العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبركِ طبيبكِ بالمخاطر والفوائد المترتبة على تناول ترازيميرا أثناء الحمل. في حالات نادرة، تمت ملاحظة انخفاض في كمية السائل (السلوي) الذي يحيط بالجنين داخل الرحم في السيدات الحوامل اللاتي يتلقين ترازيميرا. قد تكون هذه الحالة مضرة بطفلكِ في الرحم وقد تم ربطها بعدم نمو الرئتين بشكل كامل مما يؤدي إلى وفاة الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">لا ترضعي طفلكِ رضاعة طبيعية أثناء العلاج بترازيميرا ولمدة ٧ أشهر بعد آخر جرعة من ترازيميرا، حيث إنه يمكن لترازيميرا أن يمر لطفلكِ من خلال لبن الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">لا توجد بيانات متوفرة حول الخصوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ترازيميرا على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يؤثر ترازيميرا على قدرتك على قيادة السيارة أو تشغيل الآلات. إذا أصبت بأعراض أثناء العلاج مثل الدوار أو النعاس أو القشعريرة أو الحمى، ينبغي لك عدم القيادة أو استخدام الآلات حتى زوال هذه الأعراض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيحدد الطبيب كمية الـHER2 في الورم الخاص بك قبل بدء العلاج. سيتم فقط علاج المرضى الذين لديهم كمية كبيرة من الـ2HER بترازيميرا. ينبغي أن يُعطى ترازيميرا بواسطة طبيب أو ممرضة فقط. سيصف طبيبك جرعة ونظام علاج مناسبين <strong>لك</strong>. تعتمد جرعة ترازيميرا على وزن جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تركيبة ترازيميرا المستخدمة عن طريق الوريد ليست للاستخدام تحت الجلد وينبغي أن تعطى كتسريب عن طريق الوريد فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعطى تركيبة ترازيميرا المستخدمة عن طريق الوريد كتسريب عن طريق الوريد (&quot;التنقيط&quot;) مباشرةً في أوردتك. تعطى الجرعة الأولى من علاجك على مدار ٩٠ دقيقة وستتم ملاحظة حالتك من قِبل أحد متخصصي الرعاية الصحية أثناء إعطاؤك الجرعة في حالة أصبت بأي آثار جانبية. إذا تم تحمل الجرعة الأولى بشكل جيد، يمكن إعطاء الجرعات التالية على مدار ٣٠ دقيقة (انظر القسم ٢ تحت العنوان &quot;تحذيرات واحتياطات&quot;). سيعتمد عدد التسريبات التي تتلاقاها على كيفية استجابتك للعلاج. سيناقش طبيبك هذا الأمر معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من أجل منع الأخطاء المتعلقة بالدواء، فإنه من المهم فحص ملصقات القارورة للتأكد من أن الدواء الذي يتم تحضيره وإعطاؤه هو ترازيميرا (تراستوزوماب) وليس تراستوزوماب إيمتانسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء ترازيميرا كل ٣ أسابيع بالنسبة للحالات المبكرة من سرطان الثدي وحالات سرطان الثدي النقيلي وحالات سرطان المعدة النقيلي. يمكن أيضًا إعطاء ترازيميرا مرة في الأسبوع في حالات سرطان الثدي النقيلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة ترازيميرا</strong></p><p dir="RTL">إذا نسيت تناول جرعة ترازيميرا و:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان ذلك خلال فترة أسبوع واحد حدًا أقصى، فحينئذ ينبغي إعطاء جرعة المداومة المعتادة في أقرب وقت ممكن. ثم ينبغي إعطاء جرعات مداومة من ترازيميرا بعد ٧ أيام أو ٢١ يومًا فيما بعد، وفقًا لنظام العلاج المتبع إما جرعة كل أسبوع أو كل ثلاثة أسابيع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان ذلك خلال فترة تتجاوز أسبوع واحد، فحينئذ ينبغي إعطاء جرعة مبدئية من ترازيميرا مرة أخرى على مدار ٩٠ دقيقة في أقرب وقت ممكن. ثم ينبغي إعطاء جرعات مداومة من ترازيميرا بعد ٧ أيام أو ٢١ يومًا فيما بعد، وفقًا لنظام العلاج المتبع إما جرعة كل أسبوع أو كل ثلاثة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول ترازيميرا</strong></p><p dir="RTL">لا توقف استخدام هذا الدواء دون التحدث إلى طبيبك أولًا. ينبغي أخذ جميع الجرعات في وقتها الصحيح كل أسبوع أو كل ٣ أسابيع (بناءً على جدول الجرعات الخاص بك). وذلك من شأنه أن يساعد الدواء على العمل بقدر المستطاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تستغرق إزالة ترازيميرا من جسمك مدة تصل إلى ٧ أشهر. لذلك، قد يقرر طبيبك استمرار فحص وظائف قلبك حتى بعد انتهائك من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب ترازيميرا آثارًا جانبية، إلا أنها لا تصيب الجميع. قد تكون بعض تلك الآثار الجانبية خطيرة وقد تؤدي إلى الدخول إلى المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء تسريب ترازيميرا، قد تحدث قشعريرة وحمى وأعراض أخرى شبيهة بأعراض الإنفلونزا. هذه الأعراض شائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص). بعض الأعراض الأخرى المتعلقة بالتسريب: الشعور برغبة في التقيؤ (الغثيان)، القيء، الألم، زيادة التوتر العضلي والارتجاف، الصداع، الدوار، صعوبات في التنفس، الأزيز، ضغط الدم المرتفع أو المنخفض، اضطرابات نبض القلب (الخفقان أو الرفرفة أو عدم انتظام ضربات القلب)، تورم الوجه والشفتين، والطفح الجلدي، والشعور بالتعب. من الممكن أن تكون بعض هذه الأعراض خطيرة وقد توفي بعض المرضى (انظر القسم ٢ تحت العنوان &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث هذه الآثار بشكل أساسي مع التسريب الأول عن طريق الوريد (&quot;التنقيط&quot; في وريدك) وأثناء الساعات القليلة الأولى بعد بدء التسريب. عادةً ما تكون هذه الآثار مؤقتة. ستتم ملاحظة حالتك من قِبل أحد متخصصي الرعاية الصحية أثناء التسريب ولمدة ٦ أشهر على الأقل بعد بدء أول تسريب ولمدة ساعتين بعد بدء التسريبات الأخرى. إذا أصبت بتفاعل ما، فسيقوم متخصص الرعاية الصحية بإبطاء أو إيقاف التسريب وقد يعطيك علاجًا للتصدي للآثار الجانبية. من الممكن أن يستمر التسريب بعد تحسن الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحيانًا تبدأ الأعراض بعد أكثر من ٦ ساعات من بدء التسريب. إذا حدث لك ذلك، فاتصل بطبيبك على الفور. في بعض الأحيان، قد تتحسن الأعراض ثم تصبح أسوأ فيما بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الخطيرة:</p><p dir="RTL">يمكن للآثار الجانبية الأخرى أن تحدث في أي وقت أثناء العلاج بترازيميرا وليست متعلقة فقط بالتسريب. <strong>أخبر الطبيب أو الممرضة فورًا إذا لاحظت أيًا من الأعراض الجانبية التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تحدث في بعض الأحيان مشكلات بالقلب أثناء العلاج وأحيانًا بعد توقف العلاج ومن الممكن أن تكون خطيرة. تتضمن تلك المشكلات ضعف عضلة القلب مما قد يؤدي إلى فشل القلب، والتهاب البطانة المحيطة بالقلب واضطرابات نبض القلب. يمكن أن يؤدي ذلك إلى أعراض مثل انقطاع النفس (بما في ذلك انقطاع النفس في الليل)، والسعال، واحتباس السوائل (التورم) في الساقين أو الذراعين، والخفقان (رفرفة القلب أو عدم انتظام ضربات القلب) (انظر القسم ٢ تحت العنوان (&quot;فحوصات القلب&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بمراقبة قلبك بانتظام أثناء وبعد العلاج ولكن ينبغي لك إخبار طبيبك على الفور إذا لاحظت أيًا من الأعراض المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة انحلال الورم (مجموعة من المضاعفات الأيضية التي تحدث بعد علاج السرطان وتتميز بارتفاع مستويات البوتاسيوم والفوسفات في الدم وانخفاض مستويات الكالسيوم في الدم). قد تشمل الأعراض مشكلات في الكلى (الضعف وضيق التنفس والإرهاق والارتباك)، ومشكلات في القلب (رفرفة القلب أو ضربات قلب أسرع أو أبطأ)، والنوبات، والقيء أو الإسهال، والوخز في الفم أو اليدين أو القدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي من الأعراض المذكورة أعلاه عند انتهاء علاجك بترازيميرا، ينبغي لك الذهاب لرؤية طبيبك وإخباره أنك قد خضعت للعلاج بترازيميرا سابقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة المعدة (سوء الهضم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم الحمراء والبيضاء (التي تساعد على محاربة العدوى) وأحيانًا يكون مصحوبًا بحمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الملتحمة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدماع العينين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاش</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات الحرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأظافر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (الأرق)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد الصفيحات الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التكدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو خدر في أصابع اليدين والقدمين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تورم أو تقرحات في فمك و/أو حلقك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تورم أو احمرار أو الشعور بوخز في اليدين و/أو القدمين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص: </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العينين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى بالحلق&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العرق&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المثانة والجلد&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتوعك&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الثدي&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكلى&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في التوتر أو الشد العضلي &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (فرط التوتر)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرئة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين و/أو الساقين&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مثير للحكة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الرقبة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النيمومة (النعاس)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العظام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البواسير&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات الساقين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم والحلق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصمم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي ذو النتوءات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو تندب الرئتين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تأقية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب أو خلل في تجلط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البوتاسيوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو نزيف في الجزء الخلفي من العينين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صدمة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نبض القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزمة تنفسية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل تنفسي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم حاد للسوائل في الرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق حاد في الممرات الهوائية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الأكسجين في الدم بشكل غير طبيعي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس عند الاستلقاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه والشفتين والحلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات السوائل المحيطة بالجنين في الرحم بشكل غير طبيعي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل في نمو رئتي الجنين في الرحم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النمو غير الطبيعي لكليتي الجنين في الرحم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن بعض الآثار الجانبية التي تعاني منها قد تكون ناجمة عن السرطان الكامن لديك. إذا تلقيت ترازيميرا بالتزامن مع العلاج الكيميائي، فقد تكون بعض تلك الأعراض الجانبية أيضًا ناتجة عن العلاج الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><em>&nbsp;</em></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتهاء الصلاحية</strong></p><p dir="RTL">لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على ملصق القارورة والعبوة الكرتونية بعد الرمز &quot;EXP&quot;.&nbsp; في حالة ذكر الشهر والعام فقط، فإن تاريخ انتهاء الصلاحية يشير إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التخزين</strong></p><p dir="RTL">قم بتخزينه في البراد (الثلاجة) (من درجتين مئويتين إلى ٨ درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزينه في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تخزين قوارير ترازيميرا غير المفتوحة في درجة حرارة تصل إلى ٣٠ درجة مئوية لفترة فردية تصل إلى ٣ أشهر. قم بالتخلص منها بعد مرور مدة الـ٣ أشهر هذه أو بحلول موعد انتهاء الصلاحية المدون على القارورة، أيهما يأتي أولًا. قم بتسجيل تاريخ &quot;التخلص&quot; في حقل التاريخ المتاح على العبوة الكرتونية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام محاليل التسريب فورًا بعد تخفيفها. لا تستخدم ترازيميرا إذا لاحظت وجود أي جسيمات أو تغير في اللون قبل الاستعمال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم التخلص من الأدوية عبر مياه الصرف أو مع النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد هناك حاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي تراستوزوماب. تحتوي القارورة الواحدة إما على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ١٥٠ ملجم من تراستوزوماب ينبغي إذابته في ٧,٢ مل من الماء المعقم المخصص للحقن، أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٤٤٠ ملجم من تراستوزوماب ينبغي إذابته في ٢٠ مل من الماء المعقم المخصص للحقن.</p><p dir="RTL">يحتوي المحلول الناتج على حوالي ٢١ ملجم/مل من تراستوزوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكون (المكونات) الآخر (الأخرى) هو ل-هيستيدين هيدروكلوريد أحادي الهيدرات، ل-هيستيدين، سكروز، بوليسوربات ٢٠.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ترازيميرا هو مسحوق لتحضير ركازة لعمل محلول تسريب، يتم توفيره في قارورة زجاجية مزود بسدادة من المطاط تحتوي إما على ١٥٠ ملجم أو ٤٤٠ ملجم من تراستوزوماب. يُزود المسحوق في صورة كتلة بيضاء. كل عبوة كرتونية تحتوي على قارورة مسحوق واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق:</strong></p><p>Pfizer AG, Z&uuml;rich, Switzerland</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع:</strong></p><p>Pfizer Manufacturing Belgium NV, Rijksweg, Puurs, Belgium</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس/آذار ٢٠٢٢
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trazimera 150 mg powder for concentrate for solution for infusion 
Trazimera 440 mg powder for concentrate for solution for infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient
Trastuzumab (genetically engineered using CHO [Chinese hamster ovary] cells).
1 vial of Trazimera contains:
white powder for concentrate for solution for infusion, 150 mg trastuzumab.
Reconstituted Trazimera concentrate (water for injection not included) contains 21 mg/ml trastuzumab.
1 vial of Trazimera contains:
white powder for concentrate for solution for infusion, 440 mg trastuzumab.
 
 
Reconstituted Trazimera concentrate (water for injection not included) contains 21 mg/ml trastuzumab.

Excipients with known effect: 

 
L-histidine hydrochloride monohydrate, L-histidine, sucrose, polysorbate 20.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Breast cancer</em></p><p>Before beginning treatment with Trazimera, the overexpression of HER2 must have been demonstrated in the patient&#39;s tumour tissue immunohistochemically with 3+ or using molecular biological methods [determination of HER2 gene amplification by fluorescence in-situ hybridisation (FISH) or chromogenic in-situ hybridisation (CISH)].</p><p><em>&nbsp;</em></p><p><em>Metastatic breast cancer</em></p><p>Trazimera is indicated for the treatment of patients with metastatic breast cancer when the tumours overexpress HER2:</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy for the treatment of patients who have received at least one or more chemotherapy regimens for their metastatic disease.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone receptor positive metastatic breast cancer, not previously treated for their metastatic disease.</p><p>&nbsp;</p><p>No data are available on patients with breast cancer who received trastuzumab as an adjuvant treatment in the early stage.</p><p><em>&nbsp;</em></p><p><em>Early</em>-<em>stage breast cancer</em></p><p>Trazimera is indicated for the treatment of adult patients with HER2 positive early-stage breast cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following surgery, chemotherapy (neoadjuvant or adjuvant) and (if applicable) radiation therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours &gt;2 cm in diameter.</p><p><em>&nbsp;</em></p><p><em>Metastatic gastric cancer or </em>gastro-oesophageal junction cancer</p><p>Trazimera in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received chemotherapy for their metastatic disease. Trazimera should only be used in patients with metastatic gastric cancer whose tumours overexpress HER2 defined by IHC2+ and confirmed by a positive FISH+ or silver in-situ hybridisation result (SISH), or IHC3+ determined by a validated assay.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p>Trazimera treatment should only be initiated by a doctor experienced in the treatment of cancer patients.</p><p>A validated HER2 test is obligatory prior to initiation of therapy (see Pharmacological Properties).</p><p>In order to avoid medication errors, it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Trazimera (trastuzumab) and not a medicinal product with the active ingredient trastuzumab emtansine.</p><p>To ensure traceability of biotechnological medicinal products, it is recommended that the trade name and batch number should be documented for each treatment.</p><p><em>&nbsp;</em></p><p><em>Metastatic breast cancer - weekly treatment regimen</em></p><p>Trazimera should be administered by intravenous infusion. Do not administer by intravenous bolus injection.</p><p>The following initial and subsequent doses are recommended for monotherapy and for the combination with chemotherapy:</p><p><em>&nbsp;</em></p><p><em>Monotherapy</em></p><p><em>&nbsp;</em></p><p><em>Initial dose</em></p><p>The recommended initial dose of Trazimera is 4 mg/kg body weight and should be given as an intravenous infusion over a period of 90 minutes.</p><p><em>&nbsp;</em></p><p><em>Subsequent doses</em></p><p>The recommended weekly maintenance dose of Trazimera is 2 mg/kg body weight. If the initial dose is well tolerated, the maintenance dose can be administered as a 30-minute infusion.</p><p><em>&nbsp;</em></p><p><em>Combination therapy with paclitaxel or docetaxel</em></p><p>Dosage of Trazimera in combination therapy is equivalent to that of monotherapy. Paclitaxel or docetaxel is administered on the day following the first treatment dose with Trazimera. Subsequently, paclitaxel or docetaxel can be administered every 3 weeks immediately after the following Trazimera doses, if the preceding administration of Trazimera has been well tolerated. For the dosage of paclitaxel or docetaxel, see the relevant Information for Healthcare Professionals.</p><p><em>&nbsp;</em></p><p><em>Combination therapy with an aromatase inhibitor</em></p><p>Dosage of Trazimera in combination therapy is equivalent to that of monotherapy. In the marketing authorisation study, trastuzumab and anastrozole were administered on the first day. There were no restrictions on relative timing when the two were administered concomitantly. For the dosage of anastrozole, see the relevant Information for Healthcare Professionals. If the patient receives tamoxifen, this should be discontinued at least one day before initiation of combination therapy.</p><p><em>&nbsp;</em></p><p><em>Metastatic breast cancer - three-weekly treatment schedule</em></p><p><em>Monotherapy and combination therapy</em></p><p><em>&nbsp;</em></p><p>As an alternative to weekly administration, the following three-weekly regimen is recommended in monotherapy and in combination with paclitaxel, docetaxel or an aromatase inhibitor.</p><p>The initial dose of Trazimera is 8 mg/kg body weight followed by 6 mg/kg body weight 3 weeks later. The subsequent Trazimera doses of 6 mg/kg body weight are repeated at 3-week intervals. Administration takes place by infusion for about 90 minutes. If the initial dose is well tolerated, the maintenance dose can be administered as a 30-minute infusion.</p><p><em>&nbsp;</em></p><p><em>Early</em>-<em>stage breast cancer</em></p><p>For the following treatment regimens, Trazimera is administered until recurrence or for a total of 52 weeks.</p><p><em>&nbsp;</em></p><p><em>Weekly administration</em></p><p>For weekly administration, the initial dose is 4 mg/kg body weight, followed by 2 mg/kg body weight each week.</p><p><em>&nbsp;</em></p><p><em>Three-weekly administration</em></p><p>For three-weekly use, the recommended initial dose of Trazimera is 8 mg/kg body weight. The recommended dose of Trazimera at 3-week intervals is 6 mg/kg body weight, initiated 3 weeks after the initial dose.</p><p>&nbsp;</p><p>If Trazimera is continued following a combination with chemotherapy alone, 6 mg/kg body weight is administered at 3-week intervals.</p><p>How trastuzumab was investigated in combination with chemotherapy is discussed in the &quot;Properties/Effects&quot; section clinical studies on early-stage breast cancer.</p><p><em>&nbsp;</em></p><p><em>Advanced gastric cancer or gastro</em>-o<em>esophageal junction</em> cancer<em> - three-week treatment regimen</em></p><p>The initial dose is 8 mg/kg body weight followed by 6 mg/kg body weight 3 weeks later. The subsequent Trazimera doses of 6 mg/kg body weight are repeated at 3-week intervals. Administration takes place by infusion for approx. 90 minutes. If the initial dose is well tolerated, the maintenance dose can be administered as a 30-minute infusion.</p><p>&nbsp;</p><p>&nbsp;<em>Duration of treatment</em></p><p>Patients with metastatic breast cancer or advanced gastric cancer and gastro-oesophageal junction cancer should be treated with Trazimera until disease progression or until the occurrence of uncontrollable toxicity.</p><p>Patients with early-stage breast cancer should be treated for 1 year or until the disease reappears or until the occurrence of uncontrollable toxicity, whichever occurs first. Treatment of early-stage breast cancer is not recommended for a duration of more than one year (see section Pharmacological Properties).</p><p><em>&nbsp;</em></p><p>&nbsp;&nbsp;&nbsp;<em>Dose adjustment following undesirable effects</em></p><p>If the patient develops an infusion associated reaction (IAR), the rate of infusion of Trazimera should be slowed down or the infusion should be discontinued and the patient should be monitored until all observed symptoms have subsided (see Special warnings and precautions for use).</p><p>No dose reduction for trastuzumab has occurred in clinical trials. In phases of reversible, chemotherapy-induced myelosuppression, treatment with Trazimera can be continued, but patients should be carefully monitored for complications due to neutropenia during this time. The special instructions for dose reduction or interval prolongation for chemotherapy must be observed.</p><p>If the left ventricular ejection fraction (LVEF) falls by &sup3;10 percentage points below the baseline level or below 50%, the treatment should be suspended and a new LVEF measurement should be made within around 3 weeks. If the LVEF does not improve, falls further or symptomatic congestive heart failure (CHF) develops, the discontinuation of treatment with Trazimera should be seriously considered unless it is assumed that the benefit to the individual patient outweighs the risk. These patients should be referred to a cardiologist for examination and should continue to be monitored.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;</p><p><em>Elderly patients</em></p><p>Based on the data it is assumed that the availability of trastuzumabin not age-dependent (see &quot;Pharmacokinetics in special patient groups&quot;).</p><p>In clinical trials, patients &ge;65 years did not receive reduced doses of trastuzumab.</p><p>&nbsp;</p><p><strong>Pediatric population</strong></p><p>The use and safety of trastuzumabin children and adolescents &lt;18 years has not yet been investigated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trazimera is contraindicated in patients with a known hypersensitivity to trastuzumab, hamster (CHO) cell protein or any of the excipients of the medicinal product or solvent.
In metastatic breast cancer and in adjuvant treatment, Trazimera and anthracyclines should not be administered concomitantly. In neoadjuvant treatment, the concomitant administration of Trazimera and anthracyclines must be applied with caution, and only in chemotherapy-naive patients.
Trazimera is contraindicated in patients who suffer from resting dyspnoea due to their advanced malignant disease or comorbidities.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<em>Infusion associated reactions</em></p><p>Infusion associated reactions, some of which were severe, were observed in patients treated with Trazimera (typical symptoms e.g. dyspnoea, hypotension, nausea, fever, bronchial spasm, tachycardia, reduced oxygen saturation, urticaria and exanthema). These undesirable effects may occur as a result of an infusion associated reaction or as a delayed reaction. To reduce the risk of infusion associated reactions, pre-medication may be administered.</p><p>Patients should be monitored for infusion associated reactions. Interrupting the infusion may help to control these symptoms. The infusion can be resumed once the symptoms subside. These symptoms may be treated with an analgesic/antipyretic agent such as pethidine or paracetamol or an antihistamine such as diphenhydramine. Serious reactions have been successfully treated with symptomatic therapy, such as administration of oxygen, beta agonists and corticoids. In rare cases, these reactions are associated with a clinical course that may have a fatal outcome. Patients suffering from resting dyspnoea due to their advanced malignant disease or comorbidities may be at increased risk of fatal reactions to the infusion. Therefore, these patients should not be treated with Trazimera (see &quot;Contraindications&quot;).</p><p>Infusion associated reactions may be difficult to clinically distinguish from hypersensitivity reactions.</p><p>&nbsp;</p><p><em>Cardiotoxicity</em></p><p><em>General information</em></p><p>Patients treated with Trazimera are at increased risk of NYHA Class II-IV congestive heart failure or asymptomatic cardiac dysfunction. This has been observed with trastuzumab monotherapy and in combination with taxanes after anthracycline (doxorubicin, epirubicin) therapy. Cardiac failure may be moderate to severe and lead to death (see &quot;Undesirable effects&quot;). Patients with elevated cardiac risk (e.g. hypertension, coronary heart disease, congestive heart failure, diastolic dysfunction, increased age) should be treated with caution.</p><p>&nbsp;</p><p>In metastatic breast cancer and in adjuvant treatment, Trazimera and anthracyclines should not be administered concomitantly. For neoadjuvant treatment, concomitant administration of Trazimera and anthracyclines must take place with caution, and only in chemotherapy-naive patients (see &quot;Contraindications&quot;). The maximum cumulative dose of low-dose anthracycline therapy should not exceed 180 mg/m<sup>2</sup> (doxorubicin) or 360 mg/m<sup>2</sup> (epirubicin). Patients who have been treated with neoadjuvant therapy with low doses of anthracyclines in combination with Trazimera should not be administered additional cytotoxic chemotherapy after surgery. Clinical experience with neoadjuvant-adjuvant therapy in patients over 65 years is limited.</p><p>&nbsp;</p><p>Most symptomatic cardiac adverse effects occurred within the first 18 months, irrespective of the regimen used. Cumulative incidence did not increase after 3 years. The majority of cases of left ventricular dysfunction improved after discontinuation of trastuzumabtherapy and/or initiation of cardiac drug therapy.</p><p>&nbsp;</p><p>Population pharmacokinetic model simulations suggest that trastuzumab may still be present in the bloodstream for up to 7 months after discontinuation of treatment with intravenously or subcutaneously administered trastuzumab (see &quot;Pharmacokinetics&quot;). Patients who receive anthracycline after discontinuation of Trazimera are also likely to be at increased risk of cardiotoxicity.</p><p>&nbsp;</p><p>If possible, anthracycline therapy should be avoided for up to 7 months after discontinuation of Trazimera.</p><p>Before treatment with Trazimera, especially in patients previously treated with anthracycline, heart function should be monitored, including medical history and physical examination as well as ECG, echocardiogram and/or MUGA scan. For the early detection of cardiac dysfunction, patients should also continue to undergo heart function monitoring every 3 months during treatment, and after discontinuation of treatment every 6 to 24&nbsp;months after the final administration of Trazimera. Patients receiving chemotherapy containing anthracycline should continue to be monitored yearly for up to 5 years after the final administration of Trazimera, or longer if a continuous reduction of LVEF is observed.</p><p>&nbsp;</p><p>If LVEF decreases by 10 or more percentage points or drops below 50% compared to baseline, administration of Trazimera should be discontinued temporarily and a repeated LVEF measurement should be made within approximately 3 weeks. If LVEF has not improved in the meantime, or if clinically significant cardiac failure has developed, discontinuation of Trazimera should be urgently considered unless in individual cases the benefit is assessed to outweigh the risks. Patients who develop asymptomatic cardiac dysfunction should be monitored more frequently (e.g. every 6-8&nbsp;weeks). If patients show a persistent drop in left ventricular function but remain asymptomatic, the doctor should consider discontinuing treatment unless the benefit to the patient in question is regarded as being greater than the risks. These patients should be referred to a cardiologist for examination and should continue to be monitored.</p><p>The safety of continuing or resuming trastuzumabin patients with cardiac dysfunction has not been prospectively investigated. If symptomatic cardiac failure occurs during Trazimera treatment, it should be treated with the standard medication for cardiac failure. In the pivotal studies, the condition of most patients who developed cardiac failure or asymptomatic cardiac dysfunction improved under therapy with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and beta blockers.</p><p>&nbsp;</p><p><em>Adjuvant and neoadjuvant treatment</em></p><p>Patients with a history of myocardial infarction, angina pectoris requiring medication, with a prior history of or with existing congestive heart failure (NYHA Class II-IV), other cardiomyopathies, cardiac arrhythmias requiring medication, clinically significant cardiac valve disease, inadequately controlled hypertension (apart from hypertension controlled with standard medication) and pericardial effusion with an effect on haemodynamic parameters were excluded from adjuvant breast cancer studies with trastuzumab.</p><p>&nbsp;</p><p>In patients with early-stage breast cancer, an increase in the incidence of symptomatic and asymptomatic cardiac events was observed when trastuzumab was administered after anthracycline-containing chemotherapy versus a non-anthracycline-containing treatment such as docetaxel or carboplatin. The incidence was greater when trastuzumab was administered concomitantly with taxanes than when administered sequentially after taxanes. Regardless of the treatment regimen used, most symptomatic cardiac side effects occurred within the first 18&nbsp;months.</p><p>&nbsp;</p><p>The risk factors for cardiac side effects were advanced age (&gt;50 years), a low baseline value and decreasing LVEF (&lt;55%), a low LVEF before or after initiating treatment with paclitaxel, trastuzumab treatment and previous or concomitant use of antihypertensive medicinal products. In patients receiving trastuzumab after discontinuing adjuvant chemotherapy, the risk of cardiac dysfunction was associated with a higher cumulative dose of anthracyclines administered prior to initiating trastuzumab treatment and a higher body mass index (BMI&gt;25 kg/m<sup>2</sup>).</p><p>&nbsp;</p><p><em>Pulmonary reactions</em></p><p>Serious undesirable effects on the lungs during treatment with trastuzumab have been reported in the post-marketing phase (see &quot;Undesirable effects&quot;). These cases occasionally had a fatal outcome and may occur as part of an infusion associated reaction or as a delayed reaction. In addition, interstitial pulmonary disease including lung infiltration, acute respiratory distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute pulmonary oedema and respiratory insufficiency have been reported.</p><p>&nbsp;</p><p>Risk factors associated with interstitial pulmonary disease include other, previously or concomitantly performed anti-neoplastic therapies that are known to be associated with interstitial pulmonary disease, such as taxanes, gemcitabine, vinorelbine and radiation therapy. Patients who suffer from resting dyspnoea due to complications of advanced malignant disease and comorbidities may have an increased risk of pulmonary events. Therefore, these patients should not be treated with Trazimera.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacokinetic/pharmacodynamic interactions</em></p><p>No formal interaction studies with trastuzumabhave been performed in humans. Clinically relevant interactions between trastuzumab and the accompanying medicinal products used in clinical trials have not been observed.</p><p>&nbsp;</p><p>In studies where trastuzumab was administered in therapeutic doses in combination with docetaxel, carboplatin or anastrozole, neither the pharmacokinetics of these medicinal products nor those of trastuzumab were altered.</p><p>&nbsp;</p><p>The concentrations of paclitaxel and doxorubicin [as well as their main metabolites 6-&alpha;-hydroxyl paclitaxel (POH) and doxorubicinol (DOL)] were unchanged in the presence of trastuzumab. However, trastuzumab may increase the total exposure to one doxorubicin metabolite [7-deoxy-13-dihydro-doxorubicinone (D7D)]. The bioactivity of D7D and the clinical effect of increasing this metabolite are uncertain. No changes in trastuzumab concentrations were observed in the presence of paclitaxel and doxorubicin.</p><p>&nbsp;</p><p>The results of a drug interaction substudy to assess the pharmacokinetics of capecitabine and cisplatin when administered with or without trastuzumab suggest that exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not influenced by concomitant administration of cisplatin and cisplatin plus trastuzumab, respectively. However, capecitabine itself showed higher concentrations and a longer half-life in combination with trastuzumab. The data also suggest that the pharmacokinetics of cisplatin were not influenced by concomitant administration of capecitabine or capecitabine plus trastuzumab.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p><u>Women of childbearing age</u></p><p>Women of childbearing age should use effective contraception during treatment with Trazimera and for 7 months after completion of the treatment (see &quot;Pharmacokinetics&quot;).</p><p><u>&nbsp;</u></p><p>The medicinal product has harmful pharmacological effects on the pregnancy and/or the foetus/neonate.</p><p><u>&nbsp;</u></p><p>Trazimera should not be used during pregnancy, unless absolutely necessary, i.e. the potential benefit to the mother outweighs the potential risk to the foetus.</p><p>In the post-marketing setting, cases of foetal renal growth (e.g. renal hypoplasia) and/or function impairment associated with oligohydramnios, including some with fatal pulmonary hypoplasia of the foetus, have been reported in pregnant women receiving trastuzumab. Women who become pregnant should be advised of the possibility of harm to the foetus. If a pregnant woman is treated with Trazimera, or if a patient becomes pregnant during treatment with Trazimera or within 7 months after the last dose of Trazimera, close monitoring by a multidisciplinary team is indicated.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In a study in which&nbsp; cynomolgus monkeys received doses from day 120 to 150 of their gestation that corresponded to 25 times the weekly maintenance dose of trastuzumab i.v. of 2mg/kg in humans, showed that trastuzumab is secreted postpartum in breast milk. The trastuzumab exposition in utero and the presence of trastuzumab in the serum of breast-fed infant monkeys was not associated with undesirable effects on their growth or development from the time of birth to the age of one month. It is not known whether trastuzumab is secreted in human milk. However, since human IgG is secreted from the serum to the mother&#39;s milk and the risk potential for the infant is not known, breast-feeding should not take place during therapy with Trazimera.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>It is not known whether Trazimera can affect reproductive ability when administered to pregnant women.</p><p>Reproduction studies were performed on cynomolgus monkeys with dosages up to 25 times the weekly maintenance dose of trastuzumab in humans of 2 mg/kg body weight. Trastuzumab was shown to cross the placenta in the early (gestation day 20 to 50) and the late (gestation day&nbsp;120-to 150) stage of foetal development. However, the studies did not reveal any harm to foetuses or impairment of fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trastuzumab has low influence on the ability to drive and the capability to use machines. During treatment with trastuzumab dizziness or sleepiness may occur (see section &laquo;Undesirable effects&raquo;).Patients with infusion associated symptoms (see section &ldquo;Warnings and precautions&rdquo;) should be advised not to drive or use machines until the symptoms disappeared completely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of safety profile:</p><p>&nbsp;</p><p>The most serious and/or most frequently reported undesirable effects in treatment with trastuzumab are cardiotoxicity, infusion reactions, haematotoxicity (mainly neutropenia), infections and pulmonary adverse events.</p><p>NYHA Class II-IV<strong> </strong>cardiotoxicity (cardiac failure) is a common undesirable effect associated with treatment with trastuzumab and may have a fatal outcome (see &quot;Warnings and precautions&quot;).</p><p>&nbsp;</p><p>An estimated 49-54% (MBC) and 18-54% (EBC) of patients treated with trastuzumab will experience infusion-related reactions of some kind. However, most of these infusion-related undesirable effects are mild to moderate (according to NCI-CTC criteria) and occur mainly in the first few treatments, especially during the first three infusions, with frequency decreasing in the following infusions.</p><p>&nbsp;</p><p>Reactions include chills, fever, nausea, urticaria, exanthema, dyspnoea, bronchial spasm, tachycardia and hypotension (see &quot;Warnings and precautions&quot;).</p><p>Severe anaphylactic reactions requiring immediate additional intervention occur very rarely and when they do, are normally encountered during the first or second infusion of trastuzumab (see &quot;Warnings and precautions&quot;).</p><p>&nbsp;</p><p>Leucopenia, febrile neutropenia anaemia and thrombocytopaenia occur very commonly. Frequently occurring adverse events include neutropenia. The frequency with which hypoprothrombinaemia occurs is not known.</p><p>Serious pulmonary undesirable effects associated with trastuzumab are rare, but have occasionally been associated with a fatal outcome. These include lung infiltration, acute respiratory distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute pulmonary oedema and respiratory insufficiency (see &quot;Warnings and precautions&quot;).</p><p><em>&nbsp;</em></p><p><em>List of undesirable</em> <em>effects</em></p><p>Frequency categories are listed based on MedDRA terminology: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><strong>&nbsp;</strong></p><p>Undesirable effects and undesirable events which have been reported with the use of intravenous trastuzumab alone or in combination with chemotherapy in marketing authorisation clinical studies and after post-marketing are listed below.</p><p>The frequency information relates to the maximum percentage frequencies of undesirable effects which have been observed in marketing authorisation clinical studies.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table of Adverse Drug Events Reported During Clinical or Postmarketing Experience</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top"><p>Infection (24%) , Nasopharyngitis (17%)</p></td><td style="vertical-align:top"><p>Cystitis, influenza, pharyngitis, skin infections sinusitis, , rhinitis, upper respiratory tract infection, urinary tract infection, neutropenic sepsis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Meningitis, bronchitis</p><p><em>Neoplasms benign, malignant, and unspecified</em> <em>(incl. cysts and polyps).</em></p><p>Progressive malignant neoplasia, progressive neoplasia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p>Neutropenia (47%), Anaemia (28%), thrombocytopenia (16%), febrile neutropenia (23%), leukopenia (15%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe immune thrombocytopaenia with bleeding have been observed which may occur within a few hours after the infusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoprothrombinaemia, leukaemia, immune thrombocytopaenia</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, anaphylactic shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolic and nutrition disorders</em></p></td><td style="vertical-align:top"><p>Anorexia (46%), Weight increase (15%), weight decreased (23%), appetite decreased (20%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkalaemia, tumour lysis syndrome</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>Insomnia (11%)</p></td><td style="vertical-align:top"><p>Anxiety, depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lethargy, paraneoplastic cerebellar degeneration</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Paraesthesia (50%), headache (25%), lightheadedness (21%), &nbsp;dysgeusia (19%), hypoaesthesia 11%), tremor</p></td><td style="vertical-align:top"><p>Taste reduction, hypertonia (muscule hypertonia), peripheral neuropathy, giddiness, sleepiness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lethargy, coma, cerebrovascular disorders</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>Conjunctivitis (38%), lacrimation increased (21%),</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry eye.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Papillary oedema, retinal haemorrhage, madarosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Deafness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders*</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Ejection fraction decreased (11%), <sup>$</sup>cardiac flutter , <sup>$</sup>heartbeats irregular (10%)</p></td><td style="vertical-align:top"><p><sup>$</sup>Supraventricular tachyarrhythmia,(congestive) heart failure, cardiomyopathy, <sup>$</sup>palpitations</p></td><td style="vertical-align:top"><p>Pericardial effusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiogenic shock, gallop rhythm present, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>Hot flushes (17%), lymphoedema (11%)</p></td><td style="vertical-align:top"><p><sup>$</sup>Hypotension, <sup>$</sup>hypertension, vasodilatation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>Epistaxis (18%), , rhinorrhoea (18%), cough (16%), oropharyngeal pain (15%), dyspnoea (14%),</p></td><td style="vertical-align:top"><p>Asthma, pulmonary disease, pleural effusion, pneumonia</p></td><td style="vertical-align:top"><p>Pneumonitis, <sup>$</sup>wheezing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial pulmonary disease including lung infiltration, pulmonary fibrosis, respiratory insufficiency, respiratory arrest, acute pulmonary oedema, acute respiratory distress, bronchospasm, laryngeal oedema, orthopnoea, exertional dyspnoea, hiccups, acute respiratory distress syndrome, respiratory distress syndrome, oxygen saturation decreased, hypoxia, Cheyne-Stokes respiration</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Nausea (78%), diarrhoea (50%), vomiting (50%), stomatitis (40%), constipation (27%), abdominal pains (20%), , dyspepsia (14%), <sup>$</sup>lip swelling , , ,</p></td><td style="vertical-align:top"><p>Dry mouth, haemorrhoids</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastritis</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis, liver sensitivity, liver cell damage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Alopecia (94%), palmar-plantar erythrodyaesthesia (26%), erythema (23%), rash (24%), , nail toxicity (11%), nail disorders (17%), <sup>$</sup>face oedema</p></td><td style="vertical-align:top"><p>Acne, dry skin, subcutaneous bleeding, hyperhidrosis, maculopapular rash, pruritus, onychoclasis, dermatitis</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema, onychorrhexis, Stevens Johnson syndrome</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Arthralgia (28%), <sup>$</sup>muscle tightness, myalgia (35%)</p></td><td style="vertical-align:top"><p>Arthritis, back pain, bone pain, muscle cramps, neck pain, pain in limb, musculoskeletal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Membranous glomerulonephritis, glomerulonephropathy, renal failure, dysuria</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Breast inflammation/mastitis, breast pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Asthenia (51%), chest pain (11%), chills (15%), fatigue (53%), influenza-like illness (23%), infusion associated reactions (74%), pain (12%), fever (12%), peripheral oedema (17%), mucosal inflammation (23%).</p></td><td style="vertical-align:top"><p>Malaise, oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>$ </sup>Means that the incidence shown is the total incidence of several terms. Percentages are not available for individual undesirable effects.</p><p>Undesirable effects after market launch</p><p>In the post-marketing setting, rare cases of severe immune thrombocytopaenia with hemorrhage have been observed which may occur within a few hours after the infusion.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>In neoadjuvant/adjuvant study (B022227), antibodies to trastuzumab were detected during follow-up with a median duration of more than 70 months in 10.1% (30/296) of patients (treatment-related antibodies as well as antibodies occurring more frequently as a result of treatment). In 2 out of 30 trastuzumab patients, neutralising antibodies were found in samples taken from the beginning of the study. The clinical relevance of these antibodies is not known. However, pharmacokinetics, efficacy [determined by pathological complete response (pCR)] or safety [determined by the frequency of infusion associated reactions] of trastuzumab did not appear to be adversely affected by these antibodies to trastuzumab.</p><p><em>&nbsp;</em></p><p><em>* Cardiological long-term follow-up period in early</em>-<em>stage breast cancer. </em>After one year of treatment with trastuzumab and a median follow-up period of 8 years, in study BO16348, the frequency of severe chronic heart failure (NYHA class III &amp; IV) was 0.8%, and the rate of mild symptomatic and asymptomatic left ventricular dysfunction was 4.6%.</p><p>The reversibility of severe chronic heart failure (defined as the result of at least two consecutive left ventricular ejection fractions with values &ge;50% after the event) was apparent for 71.4% of the affected patients. Reversibility of mild symptomatic and asymptomatic left ventricular dysfunction was demonstrated in 79.5% of affected patients. Approximately 17% of events caused by cardiac dysfunction occurred after discontinuing treatment with trastuzumab.</p><p>In the joint evaluation of studies NSABP B-31 and NCCTG N9831 with a median follow-up period duration of 8.1 years, the patient-associated frequency of newly occurring cardiac dysfunction, measured using LVEF, remained unchanged in the AC&rarr;PH group (doxorubicin plus cyclophosphamide, followed by paclitaxel plus trastuzumab) compared to the evaluation performed in the AC&rarr;PH group after a median follow-up period of 2.0 years: a &ge;10% reduction in LVEF to under 50% was observed in 18.5% of AC&rarr;PH patients. Reversibility of left ventricular dysfunction was observed in 64.5% of patients in the AC &rarr; PH group who had symptomatic congestive heart failure and were asymptomatic at the last follow-up examination, and in 90.3% of patients who exhibited complete or partial LVEF recovery.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after market authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national pharmacovigilance centre (NPC) reporting system.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;Other GCC States:</strong></p><p><em>&nbsp;</em></p><p> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical trials have shown no experience of overdose in humans. Individual doses of more than 10 mg/kg body weight have not been tested.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: L01XC03</p><p>Trazimera is a trastuzumab biosimilar. Biosimilarity to the trastuzumab reference product has been shown in comparability studies regarding pharmaceutical quality, biological activity, pharmacokinetics, efficacy and safety.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Mechanism of action&nbsp;</u></p><p>&nbsp;</p><p>Trastuzumab is a recombinant humanised monoclonal IgG<sub>1</sub> kappa antibody produced in CHO (Chinese Hamster Ovary) cells with murine hypervariable regions of the variable region. The antibody specifically binds to the extracellular domain of human epidermal growth factor receptor&nbsp;2 (HER2).</p><p>The HER2 proto-oncogene (or c-erbB2) codes for a receptor-like transmembranous single-stranded protein 185 kDa in size, structurally related to the epidermal growth factor receptor. Overexpression of HER2 is observed in 15% to 20% of all primary breast cancers. The overall rate of HER2 positivity in advanced gastric cancer in relation to IHC3+ or IHC2+/FISH+ observed during the screening for study BO18255 is 15%. When a broader definition for IHC3+ or FISH+ for HER2 positivity is used, the rate is 22.1%. HER2 protein amplification on the cell surface of these tumour cells, which is associated with a strong activation of the HER2 protein, increases with HER2 gene amplification.</p><p>&nbsp;</p><p>As studies show, breast cancer patients with tumours that overexpress HER2 have a shorter disease-free survival time than patients without HER2-overexpressing tumours.</p><p>It has been shown both in vitro and in animals that trastuzumab inhibits the proliferation of human tumour cells that overexpress HER2. Trastuzumab is a mediator for antibody-dependent cell-mediated cytotoxicity (ADCC). In vitro data show trastuzumab-mediated ADCC, preferably on HER2-overexpressing cancer cells.</p><p>&nbsp;</p><p><em>Detection of HER2 overexpression or HER2 gene amplification in breast cancer</em></p><p>Trazimera should only be used to treat patients whose tumours have HER2 overexpression or HER2 gene amplification. HER2 overexpression should be diagnosed by an immunohistochemical assay (IHC) of fixed tumour blocks (see &ldquo;Dosage Administration&rdquo;). HER2 gene amplification should be demonstrated by fluorescence in-situ hybridisation (FISH) or chromogenic in-situ hybridisation (CISH) of fixed tumour blocks. Patients are eligible for therapy with Trazimera if they have strong HER2 overexpression as described under the 3+ classification for IHC or a positive FISH or CISH result.</p><p>&nbsp;</p><p>In order to obtain accurate and reproducible results, testing must be conducted in specialised laboratories that can ensure validation of the test methods.</p><p>&nbsp;</p><p>The following rating system is recommended for the assessment of IHC staining patterns:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Classification of staining intensity</em></p></td><td style="vertical-align:top"><p><em>Staining pattern</em></p></td><td style="vertical-align:top"><p><em>Assessment of HER2 overexpression</em></p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>No staining or membrane staining is observed in &lt;10% of the tumour cells</p></td><td style="vertical-align:top"><p>Negative</p></td></tr><tr><td style="vertical-align:top"><p>1+</p></td><td style="vertical-align:top"><p>Weak/barely perceptible membrane staining is observed in &gt;10% of the tumour cells. The cells are stained only on parts of their membrane.</p></td><td style="vertical-align:top"><p>Negative</p></td></tr><tr><td style="vertical-align:top"><p>2+</p></td><td style="vertical-align:top"><p>Weak to moderate staining of the entire membrane can be observed in &gt;10% of the tumour cells.</p></td><td style="vertical-align:top"><p>Equivocal</p></td></tr><tr><td style="vertical-align:top"><p>3+</p></td><td style="vertical-align:top"><p>Moderate to strong complete membrane staining is observed in &gt;10% of the tumour cells.</p></td><td style="vertical-align:top"><p>Positive</p></td></tr></tbody></table><p>The result of the FISH test is generally classified as positive if the ratio between the number of HER2 gene copies per tumour cell and the number of copies of chromosome 17 is greater than or equal to 2, or if chromosome 17 is not carried as a control - if more than 4 copies of the HER2 gene are present per tumour cell.</p><p>&nbsp;</p><p>The result of the CISH test is generally classified as positive if over 50% of the tumour cells have more than 5 copies of the HER2 gene per cell nucleus.</p><p>For complete information on the performance and interpretation of these tests, see the package brochures of validated FISH and CISH assays.</p><p>&nbsp;</p><p><em>Detection of HER2 </em>overexpress<em>ion or HER2 gene amplification in metastatic </em>gastric cancer<em> or </em>gastro-oesophageal junction cancer</p><p>Only a reliable and validated test may be used to determine HER2 overexpression or HER2 gene amplification. IHC is recommended as the first test modality. In cases where an additional HER2 gene amplification status is required, either a silver in-situ hybridisation (SISH) or FISH method must be used. In order to obtain accurate and reproducible results, testing must be conducted in specialised laboratories that can ensure validation of the test methods. For complete information on the performance and interpretation of these tests, see the product information for validated FISH and SISH assays.</p><p>&nbsp;</p><p>In the ToGA study, patients with either IHC3+ or FISH-positive tumours were defined as HER2 positive and included in the study. Based on the clinical trial results, the positive effects were limited to patients with the highest HER2 protein overexpression levels, defined by IHC3+ or IHC2+ and a positive FISH score.</p><p>&nbsp;</p><p>In a method comparison study (study D008548) of SISH and FISH methods for the determination of HER2 gene amplification in patients with gastric cancer, a high concordance rate (&gt;95%) was observed.</p><p>&nbsp;</p><p>Trazimera should only be used in patients whose tumour has a strong HER2 overexpression, i.e., IHC3+ or IHC2+ plus a positive FISH or SISH result.</p><p>The amplification of the HER2 gene can be detected by in-situ hybridisation, e.g. FISH or SISH of fixed tumour blocks.</p><p>The following rating system is recommended for the assessment of IHC staining patterns:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Classification</em></p></td><td style="vertical-align:top"><p><em>Surgical specimen - Staining pattern</em></p></td><td style="vertical-align:top"><p><em>Biopsy specimen - Staining pattern</em></p></td><td style="vertical-align:top"><p><em>Assessment of HER2 overexpression</em></p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>No reactivity or membrane reactivity in &lt;10% of tumour cells</p></td><td style="vertical-align:top"><p>No reactivity or membrane reactivity in any tumour cells</p></td><td style="vertical-align:top"><p>Negative</p></td></tr><tr><td style="vertical-align:top"><p>1+</p></td><td style="vertical-align:top"><p>Weak/barely perceptible membrane reactivity in &ge;10% of tumour cells; the cells are reactive only at parts of their membrane</p></td><td style="vertical-align:top"><p>Tumour cell clusters with weak/barely perceptible membrane reactivity independent of the percentage of stained tumour cells</p></td><td style="vertical-align:top"><p>Negative</p></td></tr><tr><td style="vertical-align:top"><p>2+</p></td><td style="vertical-align:top"><p>Weak to moderate complete or basolateral membrane reactivity in &ge;10% of tumour cells</p></td><td style="vertical-align:top"><p>Tumour cell clusters with weak to moderate complete basolateral or lateral membrane reactivity independent of the percentage of stained tumour cells</p></td><td style="vertical-align:top"><p>Equivocal</p></td></tr><tr><td style="vertical-align:top"><p>3+</p></td><td style="vertical-align:top"><p>Strong complete, basolateral or lateral membrane reactivity in &ge;10% of tumour cells</p></td><td style="vertical-align:top"><p>Tumour cell clusters with a strong complete, basolateral or lateral membrane reactivity independent of the percentage of stained tumour cells</p></td><td style="vertical-align:top"><p>Positive</p></td></tr></tbody></table><p>In general, the result of the FISH or SISH test is classified as positive if the ratio between the number of HER2 gene copies per tumour cell and the number of copies of chromosome 17 is greater than or equal to 2.</p><p>HER2 expression is predominantly found in the intestinal histological subtype. In contrast to breast cancer, immunohistochemical staining is usually incomplete in gastric cancer.</p><p>HER2 can be detected as a free molecule in the plasma (shedding). However, the extent of HER2 expression in the plasma does not correlate with the clinical course. There is no information on shedding in gastric cancer.</p><p>&nbsp;</p><p><em>Clinical data</em></p><p><em>Metastatic breast cancer</em></p><p>Trastuzumab has been administered as a monotherapeutic agent in clinical trials to patients with metastatic breast cancer whose tumours overexpressed HER2 and who had not responded to one or more chemotherapies of their metastatic disease (trastuzumab alone).</p><p>&nbsp;</p><p>Trastuzumab has also been used in combination with paclitaxel or docetaxel for the treatment of patients who had not previously received chemotherapy for their metastatic breast cancer. Patients who had previously received adjuvant anthracycline chemotherapy received paclitaxel (175 mg/m<sup>2</sup>, infusion duration 3 hours) with or without trastuzumab. In the pivotal study of docetaxel (100 mg/m<sup>2</sup> infused over 1 hour) with or without trastuzumab, 60% of patients previously received adjuvant anthracycline-based chemotherapy. Patients were treated with trastuzumab until progression of disease.</p><p>The efficacy of trastuzumab combined with paclitaxel in patients who have not received adjuvant chemotherapy with anthracyclines has not been studied. However, trastuzumab plus docetaxel was effective in all patients - whether or not they received adjuvant anthracycline.</p><p>&nbsp;</p><p>The test method for HER2 overexpression used in the Pivotal study (trastuzumab monotherapy and trastuzumab plus paclitaxel) to determine patient suitability was based on immunohistochemical staining of HER2 on fixed material from breast cancer tumours using monoclonal mouse antibodies CB11 and 4D5. These tissues were fixed in formalin or Bouin&#39;s solution. This assay of the clinical trial was performed in a central laboratory using a scale of 0 to 3+. Patients whose staining was classified as 2+ and 3+ were included, while those with a staining of 0 or 1+ were excluded. More than 70% of patients demonstrated an overexpression of 3+. The data suggest that the positive effects were more pronounced in patients with severe overexpression of HER2 (3+).</p><p>&nbsp;</p><p>In the pivotal study of docetaxel with or without trastuzumab, immunohistochemistry was the significant test method for the determination of HER2 overexpression. A minority of patients were tested using FISH. In this study, 87% of included patients had an IHC3+ overexpression and 95% of patients were IHC3+ and/or FISH-positive.</p><p>&nbsp;</p><p><em>Combination therapy with </em><em>trastuzumab</em> <em>and paclitaxel or docetaxel:</em></p><p>The efficacy data from the studies on monotherapy and combination therapy (with paclitaxel or docetaxel) are summarised in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Parameter</em></p></td><td colspan="4" style="vertical-align:top"><p><em>Combination therapy</em></p></td><td style="vertical-align:top"><p><em>Monotherapy</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Trastuzumab</em><br /><em>plus paclitaxel<sup>1</sup></em></p></td><td style="vertical-align:top"><p><em>Paclitaxel<sup>1</sup></em></p></td><td style="vertical-align:top"><p><em>Trastuzumab</em><br /><em>plus cocetaxel<sup>2</sup></em></p></td><td style="vertical-align:top"><p><em>Docetaxel<sup>2</sup></em></p></td><td style="vertical-align:top"><p>&nbsp;Trastuzumab <em><sup>1</sup></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n=68</p></td><td style="vertical-align:top"><p>n=77</p></td><td style="vertical-align:top"><p>n=92</p></td><td style="vertical-align:top"><p>n=94</p></td><td style="vertical-align:top"><p>n=172</p></td></tr><tr><td style="vertical-align:top"><p>Median response time (months) (95% confidence interval)</p></td><td style="vertical-align:top"><p>8.3<br />(7.3-8.8)</p></td><td style="vertical-align:top"><p>4.6<br />(3.7-7.4)</p></td><td style="vertical-align:top"><p>11.7<br />(9.3-15.0)</p></td><td style="vertical-align:top"><p>5.7<br />(4.6-7.6)</p></td><td style="vertical-align:top"><p>9.1<br />(5.6-10.3)</p></td></tr><tr><td style="vertical-align:top"><p>Median TTP (months) (95% confidence interval)</p></td><td style="vertical-align:top"><p>7.1<br />(6.2-12.0)</p></td><td style="vertical-align:top"><p>3.0<br />(2.0-4.4)</p></td><td style="vertical-align:top"><p>11.7<br />(9.2-13.5)</p></td><td style="vertical-align:top"><p>6.1<br />(5.4-7.2)</p></td><td style="vertical-align:top"><p>3.2<br />(2.6-3.5)</p></td></tr><tr><td style="vertical-align:top"><p>Median survival time (months) (95% confidence interval)</p></td><td style="vertical-align:top"><p>24.8<br />(18.6-33.7)</p></td><td style="vertical-align:top"><p>17.9<br />(11.2-23.8)</p></td><td style="vertical-align:top"><p>31.2<br />(27.3-40.8)</p></td><td style="vertical-align:top"><p>22.7<br />(19.1-30.8)</p></td><td style="vertical-align:top"><p>16.4<br />(12.3-n.k.)</p></td></tr><tr><td style="vertical-align:top"><p>Response rate (%) (95% confidence interval)</p></td><td style="vertical-align:top"><p>49%<br />(36-61)</p></td><td style="vertical-align:top"><p>17%<br />(9-27)</p></td><td style="vertical-align:top"><p>61%<br />(50-71)</p></td><td style="vertical-align:top"><p>34%<br />(25-45)</p></td><td style="vertical-align:top"><p>18%<br />(13-25)</p></td></tr></tbody></table><p>TTP = time to progression; &quot;n.k.&quot; means that the value could not be determined or had not been reached yet.</p><p><sup>1</sup>IHC3+ patient subgroup</p><p><sup>2</sup>&quot;Full Analysis&quot; population (intent-to-treat)</p><p>&nbsp;</p><p><em>Combination treatment with </em><em>trastuzumab</em> <em>and anastrozole:</em></p><p>Trastuzumab was tested in combination with anastrozole for first-line therapy in HER2-overexpressing and hormone receptor-positive (e.g. oestrogen receptor (ER) positive and/or progesterone receptor (PR) positive) postmenopausal patients with metastatic breast cancer who had not received chemotherapy for their metastatic disease. Patients with brain metastases were also excluded. Progression-free survival was significantly improved in the group with trastuzumab plus anastrozole compared to anastrozole alone (4.8 months versus 2.4&nbsp;months, p = 0.0016). In addition, the following parameters were improved by the addition of trastuzumab: overall response (16.5% versus 6.7%), clinical benefit rate (42.7% versus 27.9%) and duration until disease progression (4.8 months versus 2.4 months). There was no difference between the two groups concerning the time to response and the duration of the response. The median overall survival time was extended by 4.6 months in patients with combination therapy. The difference was not statistically significant. It should be taken into account here that more than half of patients from the group with anastrozole as a monotherapeutic agent switched to a trastuzumab -containing therapy after disease progression (crossover). 52% of patients receiving trastuzumab plus anastrozole survived for at least 2 years compared to 45% of patients who received anastrozole at the initiation of treatment (difference not statistically significant).</p><p>&nbsp;</p><p>Early-stage breast cancer</p><p>For adjuvant therapy, trastuzumab was tested in four randomised, multi-centre Phase III trials:</p><p>The aim of the study BO16348 (HERA) was to compare 3-week therapy with trastuzumab (over 1 and 2 years) with observation in patients with early-stage HER2-positive breast cancer. Patients received surgery, established chemotherapy and (if applicable) radiation therapy beforehand. In addition, the 2-year treatment with trastuzumab was compared with the corresponding one-year treatment. Patients assigned to treatment with trastuzumab received an initial dose of 8 mg/kg body weight, and subsequently 6 mg/kg body weight every 3 weeks for one or two years.</p><p>In the study BO16348 (HERA), early-stage HER2-positive breast cancers were limited to primary operable invasive adenocarcinomas of the breast with positive axillary lymph nodes or negative axillary lymph nodes for tumours with a diameter of at least 1 cm.</p><p>The results on efficacy in study BO16348 (HERA) are summarised in the following table:</p><p><em>&nbsp;</em></p><p><em>Efficacy results (BO16348/HERA study) of </em><em>trastuzumab</em> <em>(treatment for 1 year) versus non-treatment: Results of median follow-up period after 12 months* and 8 years**</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em>Parameter</em></p></td><td colspan="4" style="vertical-align:top"><p><em>Median follow-up period 12 months</em></p></td><td colspan="3" style="vertical-align:top"><p><em>Median follow-up period 8 years</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p></td><td colspan="2" style="vertical-align:top"><p><em>No </em><em>Trastuzumab</em><em>, only observation</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Trastuzumab</em><em>, 1 year</em></p></td><td colspan="2" style="vertical-align:top"><p><em>No </em><em>Trastuzumab</em><em>, only observation</em></p></td><td style="vertical-align:top"><p><em>Trastuzumab</em><em>, 1 year</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>n=1693</p></td><td colspan="2" style="vertical-align:top"><p>n=1693</p></td><td colspan="2" style="vertical-align:top"><p>n=1697***</p></td><td style="vertical-align:top"><p>n=1702***</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><em>Disease-free survival</em></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event</p></td><td colspan="2" style="vertical-align:top"><p>219 (12.9%)</p></td><td colspan="2" style="vertical-align:top"><p>127 (7.5%)</p></td><td colspan="2" style="vertical-align:top"><p>570 (33.6%)</p></td><td colspan="2" style="vertical-align:top"><p>471 (27.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients without event</p></td><td colspan="2" style="vertical-align:top"><p>1474 (87.1%)</p></td><td colspan="2" style="vertical-align:top"><p>1566 (92.5%)</p></td><td colspan="2" style="vertical-align:top"><p>1127 (66.4%)</p></td><td colspan="2" style="vertical-align:top"><p>1231 (72.3%)</p></td></tr><tr><td style="vertical-align:top"><p>P-value vs. follow-up period Hazard ratio vs. observation</p></td><td colspan="4" style="vertical-align:top"><p>&lt;0.0001<br />0.54</p></td><td colspan="4" style="vertical-align:top"><p>&lt;0.0001<br />0.76</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><em>Recurrence-free survival</em></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event</p></td><td colspan="2" style="vertical-align:top"><p>208 (12.3%)</p></td><td colspan="2" style="vertical-align:top"><p>113 (6.7%)</p></td><td colspan="2" style="vertical-align:top"><p>506 (29.8%)</p></td><td colspan="2" style="vertical-align:top"><p>399 (23.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients without event</p></td><td colspan="2" style="vertical-align:top"><p>1485 (87.7%)</p></td><td colspan="2" style="vertical-align:top"><p>1580 (93.3%)</p></td><td colspan="2" style="vertical-align:top"><p>1191 (70.2%)</p></td><td colspan="2" style="vertical-align:top"><p>1303 (76.6%)</p></td></tr><tr><td style="vertical-align:top"><p>P-value vs. follow-up period Hazard ratio vs. observation</p></td><td colspan="4" style="vertical-align:top"><p>&lt;0.0001<br />0.51</p></td><td colspan="4" style="vertical-align:top"><p>&lt;0.0001<br />0.73</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><em>Survival without disease of other organs</em></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event</p></td><td colspan="2" style="vertical-align:top"><p>184 (10.9%)</p></td><td colspan="2" style="vertical-align:top"><p>99 (5.8%)</p></td><td colspan="2" style="vertical-align:top"><p>488 (28.8%)</p></td><td colspan="2" style="vertical-align:top"><p>399 (23.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients without event</p></td><td colspan="2" style="vertical-align:top"><p>1508 (89.1%)</p></td><td colspan="2" style="vertical-align:top"><p>1594 (94.6%)</p></td><td colspan="2" style="vertical-align:top"><p>1209 (71.2%)</p></td><td colspan="2" style="vertical-align:top"><p>1303 (76.6%)</p></td></tr><tr><td style="vertical-align:top"><p>P-value vs. follow-up period<br />Hazard ratio vs. follow-up period</p></td><td colspan="4" style="vertical-align:top"><p>&lt;0.0001<br />0.50</p></td><td colspan="4" style="vertical-align:top"><p>&lt;0.0001<br />0.76</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><em>Overall survival rate (deaths)</em></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event</p></td><td colspan="2" style="vertical-align:top"><p>40 (2.4%)</p></td><td colspan="2" style="vertical-align:top"><p>31 (1.8%)</p></td><td colspan="2" style="vertical-align:top"><p>350 (20.6%)</p></td><td colspan="2" style="vertical-align:top"><p>278 (16.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients without event</p></td><td colspan="2" style="vertical-align:top"><p>1653 (97.65%)</p></td><td colspan="2" style="vertical-align:top"><p>1662 (98.2%)</p></td><td colspan="2" style="vertical-align:top"><p>1347 (79.4%)</p></td><td colspan="2" style="vertical-align:top"><p>1424 (83.7%)</p></td></tr><tr><td style="vertical-align:top"><p>P-value vs. follow-up period<br />Hazard ratio vs. follow-up period</p></td><td colspan="4" style="vertical-align:top"><p>0.24<br />0.75</p></td><td colspan="4" style="vertical-align:top"><p>0.0005<br />0.76</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>* The co-primary endpoint of disease-free survival after one year versus observation was within the predefined statistical limits</p><p>** Final analysis (including 52% of patients from the observation arm who switched to the trastuzumab arm)</p><p>*** There is a discrepancy in the overall sample size due to the fact that one small patient group was randomised after the sampling date of the 12-month median follow-up period</p><p>&nbsp;</p><p>In the interim analysis, efficacy results exceeded the statistical limits pre-defined in the protocol for the comparison of one-year therapy with trastuzumab versus observation. After a median follow-up period of 12 months, the hazard ratio (HR) for disease-free survival was 0.54 (95% CI 0.44, 0.67), which is an absolute benefit of 7.6 percentage points (85.8% vs. 78.2%) of disease-free survival after two years in favour of the trastuzumab arm.</p><p>&nbsp;</p><p>A final analysis conducted after a median follow-up period of 8 years showed that treatment with trastuzumab reduced the risk by 24% compared to the pure observation group (HR=0.76, 95% CI 0.67, 0.86). This equates to an absolute benefit of 6.4 percentage points of disease-free survival after 8 years in favour of the trastuzumab arm (one-year treatment).</p><p>In this final analysis, prolongation of trastuzumab treatment to two years showed no additional benefit compared to one-year treatment [HR disease-free survival in the intent to treat (ITT) population of 2 years vs. 1 year=0.99 (95% CI: 0.87, 1.13), p-value=0.90 and HR total survival=0.98 (0.83, 1.15); p-value=0.78]. The rate of asymptomatic cardiac dysfunction increased in the 2-year treatment arm (8.1% vs. 4.6% in the 1-year treatment arm). In the 2-year treatment arm, more patients experienced at least one adverse event of Grade 3 or Grade 4 (20.4%) than in the 1-year treatment arm (16.3%).</p><p>&nbsp;</p><p>The studies NCCTG N9831 and NSAPB B-31, which were jointly evaluated, were designed to investigate the clinical benefit of the combination of trastuzumab (H) treatment with paclitaxel (P) following AC (doxorubicin plus cyclophosphamide) chemotherapy. The study NCCTG N9831 additionally investigated the administration of trastuzumab sequentially to chemotherapy with AC/paclitaxel in patients with HER2-positive breast cancer in the early stage following surgery.</p><p>&nbsp;</p><p>In the joint evaluation of the NCCTG N9831 and NSAPB B-31 studies, early-stage breast cancers were confined to women with high-risk, operable tumours, defined as HER2 positive with positive axillary lymph nodes or HER2-positive with negative axillary lymph nodes in the presence of high-risk markers (size &gt;1 cm and ER negative or tumour size &gt;2 cm independent of hormonal state).</p><p>Trastuzumab was administered in combination with paclitaxel following AC chemotherapy. Paclitaxel was administered as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous paclitaxel - 80 mg/m<sup>2</sup> as a long-term IV infusion, administered every week for 12&nbsp;weeks</p><p>or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous paclitaxel - 175 mg/m<sup>2</sup> as a long-term IV infusion, administered every 3 weeks over 4 cycles (day 1 of each cycle).</p><p>Trastuzumab IV was administered weekly in the NCCTG 9831 and NSABP B-31 studies along with chemotherapy: initial dose 4 mg/kg body weight as a 90-minute infusion, followed by 2 mg/kg body weight as a 30-minute infusion. Treatment with trastuzumab was continued for a period of 1&nbsp;year from the date of first administration.</p><p>At the time of interim analysis, the median duration of follow-up period was 1.8 years for the AC&rarr;P arm and 2.0 years for the AC&rarr;PH arm.</p><p>&nbsp;</p><p><em>Summary of the efficacy results of the joint evaluation of studies NCCTG 9831 and NSABP B-31 at the time of final evaluation of disease-free survival*:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Parameter</em></p></td><td style="vertical-align:top"><p><em>AC&rarr;P<br />n=1679</em></p></td><td style="vertical-align:top"><p><em>AC&rarr;P+H<br />n=1672</em></p></td><td style="vertical-align:top"><p><em>P-value</em></p></td><td style="vertical-align:top"><p><em>Hazard Ratio</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Disease-free survival</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with event</p></td><td style="vertical-align:top"><p>261 (15.5%)</p></td><td style="vertical-align:top"><p>133 (8.0%)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>0.48 (0.39-0.59)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients without event</p></td><td style="vertical-align:top"><p>1418 (84.5%)</p></td><td style="vertical-align:top"><p>1539 (92.0%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Recurrence</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with event</p></td><td style="vertical-align:top"><p>235 (14.0%)</p></td><td style="vertical-align:top"><p>117 (7.0%)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>0.47 (0.37-0.58)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients without event</p></td><td style="vertical-align:top"><p>1444 (86.0%)</p></td><td style="vertical-align:top"><p>1555 (93.0%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Distant recurrence (metastasis)</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with event</p></td><td style="vertical-align:top"><p>193 (11.5%)</p></td><td style="vertical-align:top"><p>96 (5.7%)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>0.47 (0.37-0.60)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients without event</p></td><td style="vertical-align:top"><p>1486 (88.5%)</p></td><td style="vertical-align:top"><p>1576 (94.3%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Overall survival</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with event</p></td><td style="vertical-align:top"><p>92 (5.5%)</p></td><td style="vertical-align:top"><p>62 (3.7%)</p></td><td style="vertical-align:top"><p>0.014 **</p></td><td style="vertical-align:top"><p>0.67 (0.48-0.92)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients without event</p></td><td style="vertical-align:top"><p>1587 (94.5%)</p></td><td style="vertical-align:top"><p>1610 (96.3%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>* For a median follow-up period of 1.8 years for the patients in the AC&rarr;P arm and 2.0 years for the patients in the AC&rarr;PH arm</p><p>** p-value for overall survival does not exceed the pre-determined statistical limit for the comparison between AC&rarr;PH and AC&rarr;P.</p><p>&nbsp;</p><p>With regard to the primary endpoint, disease-free survival, the addition of trastuzumab to chemotherapy with paclitaxel resulted in a 52% reduction in the risk of disease recurrence. Regarding the rate of 3-year disease-free survival, the hazard ratio reflects an absolute benefit of 11.8 percentage points (87.2% vs 75.4%) in favour of the AC&rarr;PH (trastuzumab) arm.</p><p>The pre-planned final analysis of overall survival in the context of the joint evaluation of the NSABP B-31 and NCCTG N9831 studies was conducted after the occurrence of 707 deaths (median follow-up period 8.3 years in the AC&rarr;PH group). Treatment with AC&rarr;PH resulted in a statistically significant prolongation of overall survival compared to treatment with AC&rarr;P (stratified HR=0.64, 95% CI [0.55, 0.74], log rank p value &lt;0.0001). After 8 years the survival rate was estimated to be 86.9% in the AC&rarr;PH arm and 79.4% in the AC&rarr;P arm; This represents an absolute benefit of 7.4% (95% CI 4.9%, 10.0%).</p><p>&nbsp;</p><p>The BCIRG 006 study investigated the combination of trastuzumab and docetaxel either following AC chemotherapy or trastuzumab in combination with docetaxel and carboplatin in patients with early-stage HER2-positive breast cancer following surgery.</p><p>In the BCIRG 006 study, the HER2-positive breast cancers were either limited to patients with positive lymph nodes or to patients with high-risk negative lymph nodes, defined as negative (pN0) lymph node involvement and at least 1 of the following factors: tumour size &gt;2 cm, oestrogen receptor and progesterone receptor negative, histological and/or nuclear Grade 2-3 or age &lt;35 years.</p><p>In the BCIRG 006 study, trastuzumab was administered either in combination with docetaxel following AC chemotherapy (AC-DH) or in combination with docetaxel and carboplatin (DCarbH).</p><p>&nbsp;</p><p>Docetaxel was administered as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous - 100 mg/m<sup>2</sup> in the form of an IV infusion over 1 hour, administered every 3&nbsp;weeks over 4 cycles (day 2 of docetaxel cycle 1, then day 1 of each additional cycle)</p><p>or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous - 75 mg/m<sup>2</sup> in the form of an IV infusion over 1 hour, administered every 3 weeks over 6 cycles (day 2 of cycle 1, then day 1 of each additional cycle),</p><p>followed by carboplatin - at a target AUC of 6 mg/ml/min as an IV infusion over 30-60 minutes, administered every 3 weeks for a total of 6 cycles.</p><p>Trastuzumab IV was administered weekly along with chemotherapy: initial dose 4 mg/kg body weight as a 90-minute infusion, followed by 2 mg/kg body weight as a 30-minute infusion. After discontinuing therapy with chemotherapy, trastuzumab was administered every 3 weeks (initial dose 8 mg/kg body weight as a 90-minute infusion, followed by 6 mg/kg body weight as a 30-minute infusion). Treatment with trastuzumab was continued for a period of 1 year from the date of first administration.</p><p>The median duration of follow-up period was 2.9 years in the AC&rarr;D arm and 3.0 years in the AC&rarr;DH arm and in the DCarbH arm.</p><p>The efficacy results of the BCIRG 006 study are summarised in the following tables:</p><p>&nbsp;</p><p><em>Overview of </em>e<em>fficacy analyses AC&rarr;D versus AC&rarr;DH (BCIRG 006</em> study<em>)</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Parameter</em></p></td><td style="vertical-align:top"><p><em>AC&rarr;D<br />(n=1073)</em></p></td><td style="vertical-align:top"><p><em>AC&rarr;DH<br />(n=1074)</em></p></td><td style="vertical-align:top"><p><em>P-value vs. AC&rarr;D (log rank)</em></p></td><td style="vertical-align:top"><p><em>Hazard Ratio vs. AC&rarr;D (95% CI)</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Disease-free survival</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients with event</p></td><td style="vertical-align:top"><p>195 (18.2%)</p></td><td style="vertical-align:top"><p>134 (12.5%)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>0.61 (0.49-0.77)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients without event</p></td><td style="vertical-align:top"><p>878 (81.8%)</p></td><td style="vertical-align:top"><p>940 (87.5%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Distant metastases</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients with event</p></td><td style="vertical-align:top"><p>144 (13.4%)</p></td><td style="vertical-align:top"><p>95 (8.8%)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>0.59 (0.46-0.77)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients without event</p></td><td style="vertical-align:top"><p>929 (86.6%)</p></td><td style="vertical-align:top"><p>979 (91.2%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Death (event concerning overall survival)</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients with event</p></td><td style="vertical-align:top"><p>80 (7.5%)</p></td><td style="vertical-align:top"><p>49 (4.6%)</p></td><td style="vertical-align:top"><p>0.0024</p></td><td style="vertical-align:top"><p>0.58 (0.40-0.83)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients without event</p></td><td style="vertical-align:top"><p>993 (92.5%)</p></td><td style="vertical-align:top"><p>1025 (95.4%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>AC&rarr;D=doxorubicin plus cyclophosphamide, followed by docetaxel; AC&rarr;DH=doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab; CI=confidence interval</p><p>&nbsp;</p><p><em>Overview of </em>e<em>fficacy analyses AC&nbsp;&rarr;&nbsp;D versus DCarbH (study BCIRG 006)</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Parameter</em></p></td><td style="vertical-align:top"><p><em>AC&rarr;D<br />(n=1073)</em></p></td><td style="vertical-align:top"><p><em>DCarbH<br />(n=1075)</em></p></td><td style="vertical-align:top"><p><em>P-value vs. AC&rarr;D (log rank)</em></p></td><td style="vertical-align:top"><p><em>Hazard Ratio vs. AC&rarr;D (95% CI)</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Disease-free survival</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients with event</p></td><td style="vertical-align:top"><p>195 (18.2%)</p></td><td style="vertical-align:top"><p>145 (13.5%)</p></td><td style="vertical-align:top"><p>0.0003</p></td><td style="vertical-align:top"><p>0.67 (0.54-0.83)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients without event</p></td><td style="vertical-align:top"><p>878 (81.8%)</p></td><td style="vertical-align:top"><p>930 (86.5%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Distant metastases</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients with event</p></td><td style="vertical-align:top"><p>144 (13.4%)</p></td><td style="vertical-align:top"><p>103 (9.6%)</p></td><td style="vertical-align:top"><p>0.0008</p></td><td style="vertical-align:top"><p>0.65 (0.50-0.84)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients without event</p></td><td style="vertical-align:top"><p>929 (86.6%)</p></td><td style="vertical-align:top"><p>972 (90.4%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Death (event concerning overall survival)</em></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients with event</p></td><td style="vertical-align:top"><p>80 (7.5%)</p></td><td style="vertical-align:top"><p>56 (5.2%)</p></td><td style="vertical-align:top"><p>0.0182</p></td><td style="vertical-align:top"><p>0.66 (0.47-0.93)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients without event</p></td><td style="vertical-align:top"><p>993 (92.5%)</p></td><td style="vertical-align:top"><p>1019 (94.8%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>AC&rarr;D = doxorubicin plus cyclophosphamide, followed by docetaxel; DCarbH = docetaxel, carboplatin and trastuzumab; CI=confidence interval</p><p>With respect to the primary endpoint, event-free survival, the hazard ratio in the BCIRG 006 study represents an absolute benefit in 3-year disease-free survival of 5.8 percentage points (86.7 vs. 80.9%) in favour of the AC&nbsp;&rarr;&nbsp;DH (trastuzumab) arm and 4.6 percentage points (85.5 vs. 80.9%) in favour of the DCarbH (trastuzumab) arm compared to AC&rarr;D.</p><p>&nbsp;</p><p>With respect to the secondary endpoint, overall survival, the treatment with AC&rarr;DH reduced the risk of death by 42% compared to AC&rarr;D; In the patients treated with DCarbH, the risk of death was reduced by 34% compared to AC&rarr;D.</p><p>In the study BCIRG 006, 213/1075 patients in the DCarbH arm, 221/1074 patients in the AC&rarr;DH arm and 217/1073 in the AC&rarr;D arm had a Karnofsky index of &le;90 (either 80 or 90). No benefit for disease-free survival was found in this patient subgroup (hazard ratio=1.16, 95% CI [0.73, 1.83] for DCarbH vs. AC&rarr;D, hazard ratio 0.97, 95% CI [0.60, 1.55] for AC&rarr;DH vs. AC&rarr;D).</p><p>&nbsp;</p><p><em>Neoadjuvant/Adjuvant treatment</em></p><p>The MO16432 (NOAH) study investigated the administration of trastuzumab along with a total of 10&nbsp;cycles of neoadjuvant chemotherapy containing both an anthracycline and a taxane (doxorubicin (A) and paclitaxel (P) plus trastuzumab (H) followed by P+H, followed by cyclophosphamide/methotrexate/fluorouracil (CMF) plus H, followed by adjuvant trastuzumab up to a total treatment duration of 1 year) in patients with newly diagnosed locally advanced (stage III) or inflammatory HER-2 positive breast cancer.</p><p>&nbsp;</p><p>The median duration of the follow-up period in the trastuzumab arm was 3.8 years. Pathological complete remission is defined as the absence of an invasive tumour in the breast as well as in the axillary lymph nodes.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Parameter</em></p></td><td style="vertical-align:top"><p><em>Chemotherapy + </em><em>Trastuzumab</em> <em>(n=115)</em></p></td><td style="vertical-align:top"><p><em>Chemotherapy alone (n=116)</em></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Event-free survival</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with an event</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>0.65 (0.44, 0.96) p=0.0275</p></td></tr><tr><td style="vertical-align:top"><p>Overall pathological complete remission (95% CI)</p></td><td style="vertical-align:top"><p>40% (31.0, 49.6)</p></td><td style="vertical-align:top"><p>20.7% (13.7, 29.2)</p></td><td style="vertical-align:top"><p>p=0.0014</p></td></tr></tbody></table><p>With respect to the primary endpoint, event-free survival, the addition of trastuzumab to neoadjuvant chemotherapy followed by adjuvant trastuzumab for a total of 52 weeks resulted in a 35% reduction in the risk of recurrence/progression of the disease (hazard ratio: 0.65 [95% CI: 0.44-0.96]; p&lt;0.0275). After 3 years, 65% of the patients in the trastuzumab arm and 52% in the control arm were without an event. This reflects an improvement of 13% in favour of the trastuzumab arm.</p><p>&nbsp;</p><p><em>CNS metastases</em></p><p>In the HERA study, a difference of 0.3% in relation to CNS metastases was determined in the trastuzumab group with regard to the localisation of first recurrences (1.2% of patients compared with 0.9% of patients in the control group). Overall, however, the incidence of CNS metastases (primary and secondary recurrence) was similar in the two therapy groups (23 patients in the observation group compared to 25 in the trastuzumab group). This indicates the likelihood that, at the end of adjuvant chemotherapy, micrometastases were present in the CNS with approximately equal frequency in the two treatment groups.</p><p>&nbsp;</p><p>According to the joint evaluation of the NCCTG N9831 and NSAPB B-31 studies, isolated brain metastases were the initial event in the trastuzumab group more frequently than in the control group (21 vs. 11 in the B-31 study and 12 versus 4 in the N9831 study). Patients in the B-31 study were followed up for further recurrences after the occurrence of the first distant metastases. In this study, brain metastases were diagnosed as a first or secondary event in 28 patients of the trastuzumab group and 35 patients of the control group (hazard ratio 0.79, p=0.35).</p><p>&nbsp;</p><p>Thus the incidence of brain metastases in the trastuzumab group was not higher than in the control group. The varying frequency of the occurrence of brain metastases as the first event in patients in the control group can likely be attributed to an earlier relapse in another organ system.</p><p>&nbsp;</p><p><em>Metastatic adenocarcinoma of the stomach or gastro-oesophageal</em> <em>junction:</em></p><p>The efficacy results of the BO18255 study are summarised in the following table. The study included patients who had not yet received treatment for metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. The primary endpoint was overall survival. At the time of analysis, a total of 349 of the randomised patients had died: 182 patients (62.8%) in the control arm and 167 patients (56.8%) in the treatment arm. The causes of most deaths were related to the underlying cancer.</p><p>In the trastuzumab+ capecitabine/5-FU and cisplatin arm, overall survival was significantly better than in the arm with capecitabine/5-FU and cisplatin (p=0.0046, log rank test). Median duration of survival was 11.1 months when treated with capecitabine/5-FU and cisplatin, and 13.8 months with trastuzumab + capecitabine/5-FU and cisplatin. The risk of death in the trastuzumab arm decreased by 26% compared to patients in the capecitabine/5-FU arm (hazard ratio [HR] 0.74 95% CI [0.60-0.91]).</p><p>Post-hoc analyses of the subgroups showed that treatment of tumours with higher HER2 protein concentrations (IHC2+ / FISH+ and IHC3+/ independent of the FISH status) resulted in a more pronounced treatment effect. Mean overall survival of the group with increased HER2 expression was 11.8 months versus 16 months, HR 0.65 (95% CI 0.51-0.83), and the mean survival-free survival was 5.5 months versus 7.6 months, HR 0.64 (95% CI 0.51-0.79) for capecitabine /5-FU and cisplatin and for trastuzumab + capecitabine /5-FU and cisplatin, respectively.</p><p>&nbsp;</p><p><em>Summary of efficacy data (BO18255</em> <em>study):</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Population/Parameter</em></p></td><td style="vertical-align:top"><p><em>FP n&nbsp;=&nbsp;290</em></p></td><td style="vertical-align:top"><p><em>H+FP n&nbsp;=&nbsp;294</em></p></td><td style="vertical-align:top"><p><em>HR (95% CI)</em></p></td><td style="vertical-align:top"><p><em>P-value</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Total population:</em></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival (in months)</p></td><td style="vertical-align:top"><p>11.1</p></td><td style="vertical-align:top"><p>13.8</p></td><td style="vertical-align:top"><p>0.74<br />(0.60-0.91)</p></td><td style="vertical-align:top"><p>0.0046</p></td></tr><tr><td style="vertical-align:top"><p>Median progression-free survival (in months)</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>0.71 (0.59-0.85)</p></td><td style="vertical-align:top"><p>0.0002</p></td></tr><tr><td style="vertical-align:top"><p>Total response rate, %</p></td><td style="vertical-align:top"><p>34.5%</p></td><td style="vertical-align:top"><p>47.3%</p></td><td style="vertical-align:top"><p>1.70<sup>a</sup> (1.22-2.38)</p></td><td style="vertical-align:top"><p>0.0017</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>IHC3+<em> (n=287)</em></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival (in months)</p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>17.9</p></td><td style="vertical-align:top"><p>0.59 (0.43-0.81)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Median progression-free survival (in months)</p></td><td style="vertical-align:top"><p>5.7%</p></td><td style="vertical-align:top"><p>8.4%</p></td><td style="vertical-align:top"><p>0.59<br />(0.45-0.78)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>IHC2+ </em>a<em>nd FISH+ (n=&nbsp;159)</em></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival (in months)</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>12.3</p></td><td style="vertical-align:top"><p>0.75<br />(0.51-1.11)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Median progression-free survival (in months)</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>0.73<br />(0.53-1.03)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Gastric cancer</em></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival (in months)</p></td><td style="vertical-align:top"><p>11.1</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>0.76<br />(0.60-0.96)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Median progression-free survival (in months)</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>6.3</p></td><td style="vertical-align:top"><p>0.73<br />(0.60-0.90)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Gastro-oesophageal</em> <em>junction</em></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival (in months)</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>10.9</p></td><td style="vertical-align:top"><p>0.67 (0.42-1.08)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Median progression-free survival (in months)</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>0.61<br />(0.40-0.93)</p></td><td style="vertical-align:top"><p>n.a.<sup>b</sup></p></td></tr></tbody></table><p>FP: fluoropyrimidine/cisplatin</p><p>H+FP: fluoropyrimidine/cisplatin + trastuzumab</p><p><sup>a </sup>odds ratio</p><p><sup>b </sup>p-values for subgroups are not listed because the power is not sufficient to show differences between the study arms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of trastuzumab were assessed in a population pharmacokinetics model analysis which used pooled data from 1&#39;582 subjects who received intravenous trastuzumab from 18 studies of phase I, II and III.</p><p>&nbsp;</p><p><em>Absorption</em></p><p>No information</p><p>&nbsp;</p><p><em>Distribution</em></p><p>&nbsp;</p><p>In the following tables, the population-related PK exposure prognoses (with the 5<sup>th</sup>-95th percentile) and the PK parameter values were shown at clinically relevant concentrations (C<sub>max</sub> and C<sub>min</sub>) in breast cancer patients and in AGC patients who were treated with the permitted dose regimes q1w and q3w.</p><p><em>&nbsp;</em></p><p><em>Population-related PK exposure prognoses in cycle 1 (with the median 5<sup>th</sup>-95th percentile) for intravenous regimens in breast cancer and AGC patients</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Dosage</em></p></td><td style="vertical-align:top"><p><em>Primary tumour type</em></p></td><td style="vertical-align:top"><p><em>N</em></p></td><td style="vertical-align:top"><p><em>C<sub>min</sub><br />(&micro;g/ml)</em></p></td><td style="vertical-align:top"><p><em>C<sub>max</sub><br />(&micro;g/ml)</em></p></td><td style="vertical-align:top"><p><em>AUC<br />(&micro;g day/ml)</em></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>8 mg/kg +<br />6 mg/kg q3w</p></td><td style="vertical-align:top"><p>MBC/EBC</p></td><td style="vertical-align:top"><p>1195</p></td><td style="vertical-align:top"><p>29.4<br />(5.8-59.5)</p></td><td style="vertical-align:top"><p>178<br />(117-291)</p></td><td style="vertical-align:top"><p>1373<br />(736-2245)</p></td></tr><tr><td style="vertical-align:top"><p>AGC</p></td><td style="vertical-align:top"><p>274</p></td><td style="vertical-align:top"><p>23.1<br />(6.1-50.3)</p></td><td style="vertical-align:top"><p>132<br />(84.2-225)</p></td><td style="vertical-align:top"><p>1109<br />(588-1938)</p></td></tr><tr><td style="vertical-align:top"><p>4 mg/kg +<br />2 mg/kg qw</p></td><td style="vertical-align:top"><p>MBC/EBC</p></td><td style="vertical-align:top"><p>1195</p></td><td style="vertical-align:top"><p>37.7<br />(12.3-70.9)</p></td><td style="vertical-align:top"><p>88.3<br />(58-144)</p></td><td style="vertical-align:top"><p>1066<br />(586-1754)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Population-related P</em>K<em> exposure prognoses in </em>steady-state<em> (with the 5th-95th percentile) for intravenous regimens in breast cancer and AGC patients</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Dosage</em></p></td><td style="vertical-align:top"><p><em>Primary tumour type</em></p></td><td style="vertical-align:top"><p><em>N</em></p></td><td style="vertical-align:top"><p><em>C<sub>min,ss</sub><br />(&micro;g/ml)</em></p></td><td style="vertical-align:top"><p><em>C<sub>max,ss</sub><br />(&micro;g/ml)</em></p></td><td style="vertical-align:top"><p><em>AUC<sub>ss</sub><br />(&micro;g.day/ml)</em></p></td><td style="vertical-align:top"><p><em>Time </em>to <em>steady</em>-<em>state (weeks)</em></p></td><td style="vertical-align:top"><p><em>Total CL range in steady</em>-<em>state (l/day)</em></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>8 mg/kg +<br />6 mg/kg q3w</p></td><td style="vertical-align:top"><p>MBC/EBC</p></td><td style="vertical-align:top"><p>1195</p></td><td style="vertical-align:top"><p>47.4<br />(5-115)</p></td><td style="vertical-align:top"><p>179<br />(107-309)</p></td><td style="vertical-align:top"><p>1794<br />(673-3618)</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.173-0.283</p></td></tr><tr><td style="vertical-align:top"><p>AGC</p></td><td style="vertical-align:top"><p>274</p></td><td style="vertical-align:top"><p>32.9<br />(6.1-88.9)</p></td><td style="vertical-align:top"><p>131<br />(72.5-251)</p></td><td style="vertical-align:top"><p>1338<br />(557-2875)</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0.189-0.337</p></td></tr><tr><td style="vertical-align:top"><p>4 mg/kg +<br />2 mg/kg qw</p></td><td style="vertical-align:top"><p>MBC/EBC</p></td><td style="vertical-align:top"><p>1195</p></td><td style="vertical-align:top"><p>66.1<br />(14.9-142)</p></td><td style="vertical-align:top"><p>109<br />(51.0-209)</p></td><td style="vertical-align:top"><p>1765<br />(647-3578)</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.201-0.244</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Trastuzumab washout</em></p><p>The washout period for trastuzumab was assessed using the respective population PK model following intravenous and subcutaneous administration. The results of these simulations indicate that at least 95% of the patients achieved trastuzumab serum concentrations of &lt;1 &mu;g/ml 7&nbsp;months after the last dose (approximately 3% of the population-related prognosticised Cmin, ss and approx. 97% washout).</p><p>&nbsp;</p><p><em>Circulating HER2 antigen</em></p><p>Breast cancer: Measurable concentrations of the circulating extracellular domain of the HER2 receptor (&quot;shed antigen&quot;) were detected in the serum of 64% of patients with HER2-overexpressing breast tumours (up to 1880 ng/ml; median=11 ng/ml). Patients with higher baseline values of circulating HER2 antigen tended to have lower minimal serum concentrations of trastuzumab. Most patients with increased circulating antigen levels achieved target serum concentrations for trastuzumab by week 6 over the course of the weekly dosing regimen. No significant relationship could be observed between the baseline value of the circulating antigen and clinical efficacy.</p><p>In patients with gastric cancer or gastro-oesophageal junction cancer, no data are available on the amounts of circulating HER2 antigen.</p><p>&nbsp;</p><p>Linearity/non-linearity</p><p>A two-compartment model with parallel linear and non-linear elimination from the central compartment described the concentration-time profile of trastuzumab. Due to the non-linear elimination, the overall clearance increased with decreasing concentrations. The linear clearance was 0.127 l/day for breast cancer (MBC/EBC) and 0.176&nbsp;l/day for AGC. The maximum elimination rate (V<sub>max</sub>) was 8.81 mg/day for non-linear elimination and the Michaelis-Menten constant (Km) was 8.92 mg/l. The volume in the central compartment was 2.62 l in patients with breast cancer and 3.63 l in patients with AGC.</p><p><em>&nbsp;</em></p><p><em>Pharmacokinetics</em> <em>of special patient groups</em></p><p>&nbsp;&nbsp;</p><p>Hepatic impairment</p><p>No detailed pharmacokinetic studies have been conducted in patients with hepatic impairment.</p><p>Renal impairment</p><p>No detailed pharmacokinetic studies have been conducted in patients with renal impairment. It was shown in a population pharmacokinetic analysis that renal impairment does not affect the availability of trastuzumab.</p><p>No effect was found for serum creatinine on the pharmacological availability of trastuzumab.</p><p>Elderly patients</p><p>No detailed pharmacokinetic studies have been conducted in elderly patients. The age of the patients had no influence on the trastuzumab pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety pharmacology/Long-term toxicity (or repeat dose toxicity)</p><p>&nbsp;</p><p>Trastuzumab was well tolerated by mice (non-binding species) and cynomolgus monkeys (binding species) in single dose toxicity studies and toxicity studies with repeated doses of up to 6 months in duration. No signs of acute or chronic toxicity have been identified.</p><p>Two non-clinical toxicity studies to clarify the cardiotoxic effects of trastuzumab were performed with long-tailed macaques (cynomolgus monkeys).</p><p>The effects of trastuzumab were studied in animals suffering from manifest cardiac damage caused by pretreatment with doxorubicin. After conclusion of treatment with trastuzumab, no changes occurred within parameters that indicate cardiac muscle necrosis. The results showed changes in one parameter, e-point septal separation (EPSS), but not in two other parameters - fractional shortening (FS) and velocity of circumferential fibre shortening (Vcf) that would have indicated impaired cardiac function.</p><p>In one study, the adverse effects of combination therapy with doxorubicin and trastuzumab on cardiac function as well as on erythrocytes and leukocytes were compared with the corresponding adverse effects of monotherapy with the respective medicinal products. The adverse effects of combination therapy had a slightly higher degree of severity and a longer duration than the adverse effects of monotherapy with doxorubicin. Monotherapy with trastuzumab did not show any undesirable effects.</p><p>&nbsp;</p><p>Carcinogenicity</p><p>&nbsp;</p><p>&nbsp;</p><p>No carcinogenicity studies have been conducted to investigate the carcinogenic potential of Trazimera.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;</p><p>Reproductive toxicity</p><p>Reproduction studies conducted with Cynomolgus monkeys with doses of trastuzumab up to 25&nbsp;times the weekly human dose of 2 mg/kg showed no signs of fertility impairment in women. The influence on the fertility of male animals has not been tested. Studies on teratogenicity and toxicity at the end of gestation and on placental transfer did not indicate any reproductive toxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L-histidine hydrochloride monohydrate, L-histidine,&nbsp;sucrose, polysorbate 20.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No incompatibility has been observed between trastuzumab and polyvinyl chloride, polyethylene or polypropylene bags as well as glass bottles.</p><p>Glucose solution (5%) should not be used since it induces protein aggregation.</p><p>Trazimera should not be mixed or diluted with other medicinal products since no compatibility studies were conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                No incompatibility has been observed between trastuzumab and polyvinyl chloride, polyethylene or polypropylene bags as well as glass bottles.
Glucose solution (5%) should not be used since it induces protein aggregation.
Trazimera should not be mixed or diluted with other medicinal products since no compatibility studies were conducted.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Please add Keep out of the reach of children.</p><p>Store the vial of powder for concentrate for solution for infusion in the refrigerator (2‑8&nbsp;&deg;C).</p><p>&nbsp;</p><p>Unopened vials of Trazimera may be stored at room temperature (up to 30&deg;C) in the original packaging protected from light for a single period of up to 3 months. Once removed from refrigeration and stored under these conditions, discard after 3 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>150 mg:</em></p><p>1 vial of Trazimera (Trastuzumab)</p><p>&nbsp;</p><p><em>440 mg:</em></p><p>Pack of 1 vial of Trazimera (Trastuzumab)</p><p>&nbsp;</p><p>&nbsp;</p><p>Trazimera is packaged in a Type I clear glass vial with a chlorobutyl stopper and crimp seal having a flip-off cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Handling instructions for Trazimera 150 mg </em></p><p><em>&nbsp;</em></p><p><em>Preparation for use:</em></p><p>The vial of Trazimera is reconstituted with 7.2 ml sterile water for injection (not supplied). Do not use other reconstitution agents. This results in 7.4 ml solution for a single dose containing 21&nbsp;mg/ml trastuzumab and having a pH of about 6.0.</p><p>During reconstitution of Trazimera and dilution to the infusion solution, avoid shaking and excessive foam formation to prevent any possible precipitation and a reduction of the dissolved amount of Trazimera. Rapid injection from a syringe must also be avoided.</p><p>&nbsp;</p><p><em>Instructions for reconstitution:</em></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using a sterile syringe, slowly inject 7.2 ml of sterile water for injection into the Trazimera powder in the vial.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoroughly swirl the vial. DO NOT SHAKE!</p><p>Slight foam formation during the reconstitution process is not unusual. Allow the vial to rest for about 5 minutes after reconstitution. The solution should subsequently be essentially free of visible particles.</p><p>The reconstituted preparation is a colourless to slightly yellow brown transparent solution.</p><p>&nbsp;</p><p><em>Handling instructions for Trazimera 440 mg </em></p><p><em>Preparation for use:</em></p><p>A suitable aseptic method should be used.</p><p>For the preparation, water for injection can also be used. Such preparations must be used immediately and the residues discarded. The use of other solvents is to be avoided.</p><p>During reconstitution of Trazimera and dilution to the infusion solution, avoid shaking and excessive foam formation to prevent any possible precipitation and a reduction of the dissolved amount of Trazimera. Rapid injection from a syringe must also be avoided.</p><p>&nbsp;</p><p><em>Instructions for reconstitution:</em></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using a sterile syringe, slowly inject 20 ml of water into the existing Trazimera powder in the vial.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoroughly swirl the vial. DO NOT SHAKE!</p><p>Slight foam formation during the reconstitution process is not unusual. Allow the vial to rest for about 5 minutes after reconstitution. The solution should subsequently be essentially free of visible particles.</p><p>The reconstituted preparation is a colourless to slightly yellow brown transparent solution.</p><p>&nbsp;</p><p><em>Handling instructions for vials of Trazimera </em></p><p><em>Dilution of the reconstituted solution</em></p><p>The volume of reconstituted solution required to treat the affected patient is determined as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on an initial dose of trastuzumab 4 mg/kg body weight or trastuzumab 2 mg/kg body weight doses administered weekly:</p><p>&nbsp;</p><p><strong>Volume</strong> (mL)= <strong><u>Body weight</u></strong><u> (kg) x <strong>dose</strong> (<strong>4</strong> mg/kg for loading or <strong>2</strong> mg/kg for maintenance)</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>21</strong> (mg/mL, concentration of reconstituted solution)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on an initial dose of trastuzumab 8 mg/kg body weight or additional doses of trastuzumab 6 mg/kg body weight administered every three weeks:</p><p>&nbsp;</p><p><strong>Volume</strong> (mL)= <strong><u>Body weight</u></strong><u> (kg) x <strong>dose</strong> (<strong>8</strong> mg/kg for loading or <strong>6</strong> mg/kg for maintenance)</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>21</strong> (mg/mL, concentration of reconstituted solution)</p><p>&nbsp;</p><p>A corresponding amount of the reconstituted solution should be withdrawn from the vial (either from a 150 mg or 440 mg container) using a sterile needle or syringe and added to an infusion bag or glass bottle with 250 ml of 0.9% sodium chloride solution. Do not use glucose solution (5%) (see &quot;Incompatibilities&quot;). The bag or glass bottle should be carefully rotated to mix the solution without foaming.</p><p>When preparing the concentrate and the ready infusion solution particular attention should be paid to ensure sterility of the solutions.</p><p>Parenteral medicinal products should be examined by means of visual inspection prior to administration for suspended particles and discolouration.</p><p>The infusion should be used immediately after preparation.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><em>Disposal</em></p><p>After treatment or expiry, unused medicinal products must be returned in the original packaging to the place where dispensed (doctor or pharmacist) for proper disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER 

Pfizer PFE Switzerland GmbH, Zürich, Switzerland


Manufacturer:
Pfizer Manufacturing Belgium NV, Rijksweg, Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>